Document:

Technology License Agreement

 Exhibit 10.37 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 TECHNOLOGY LICENSE AGREEMENT 

This Agreement (the “Agreement”), made and effective as of the Effective Date, by and between Celexion, LLC, a Delaware limited
liability company having its principal place of business at [***] (hereinafter referred to as “Celexion” or “Licensor”) and DNP Green Technology, Inc., a Delaware corporation having its principal place of business at 1250
Rene-Levesque West, Suite 4110, Montreal, QC, Canada, H3B 4W8 (hereinafter referred to as “DNP Green” or “Licensee”). 
 Celexion and DNP Green shall also hereinafter be referred to individually as “Party” and collectively as “Parties”. 

RECITALS 
 WHEREAS, Celexion has filed [***] patent [***] listed in Schedule A attached hereto that describe novel metabolic pathways to producing a platform of 6-carbon chemicals (the “Celexion Patent
[***]”); 
 WHEREAS, DNP Green desires to obtain an exclusive license to use the Celexion Patent [***] and other related
rights according to the terms hereof, and Celexion is willing to grant such license and rights to DNP Green. 
 NOW, THEREFORE,
in consideration of these premises and the rights and obligations specified herein, Celexion and DNP Green agree as follows: 
 ARTICLE I
DEFINITIONS 
  

	1.1	“Affiliate” means any corporation, firm, limited liability company, partnership or other entity that directly or indirectly controls or is controlled
by or is under common control with a Party to this Agreement. For the purpose of this definition, control means ownership, directly or through one or more Affiliates, of fifty percent (50%) (or such lesser percentage which is the maximum
allowed to be owned by a foreign entity in a particular jurisdiction) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation, or fifty percent (50%) (or such lesser percentage which is the
maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in any partnership, or any other arrangement whereby a Party
controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity. 

  

	1.2	“Celexion Patent Rights” means (a) the Celexion Patent [***] and patent applications later filed on Work Plan Intellectual Property owned by [***],
(b) any substitutions, divisions, continuations, continuations-in-part thereof,(c) any patents issuing therefrom, (d) any reissues, renewals, re-examinations, extensions, supplementary protection certificates and the like of any such
patents or patent applications, and (e) counterparts of any of the foregoing in any other jurisdiction. 

  

					
	 Celexion and DNP
	 	1	  	Confidential

 * Confidential
treatment requested 

	1.3	“Confidential Information” means technical and business information owned or controlled by either Party (the “Disclosing Party”) that is
designated in writing to be Confidential (or a similar legend) and disclosed to the other Party (the “Receiving Party”); or, if disclosed orally or visually, such technical and business information that (i) is identified as
constituting Confidential Information at the time of disclosure, and (ii) a summary thereof is confirmed in writing by the Disclosing Party to be Confidential Information within thirty (30) days of the initial disclosure; provided that the
term and obligations of this Agreement shall not apply to information that: 

  

	 	(a)	is or becomes known to the public through no fault of the Receiving Party; or 

 

	 	(b)	is already known to the Receiving Party prior to its receipt from the Disclosing Party, as shown by the prior written records of the Receiving Party; or

  

	 	(c)	becomes known to the Receiving Party by disclosure from a third party who has a lawful right to disclose the information and who did not receive the information
directly or indirectly from the Disclosing Party; or 

  

	 	(d)	is subsequently developed by or for the Receiving Party, provided that such subsequently developed information is not derived from or based on Confidential Information
of the Disclosing Party and is developed by employees or contractors who did not have access to Confidential Information. 

 Information disclosed under this Agreement shall not be deemed to be within the foregoing exceptions merely because such information is embraced by more general knowledge in the public domain or in the
Receiving Party’s possession. In addition, no combination of features shall be deemed to be within the foregoing exceptions merely because individual features are in the public domain or in the Receiving Party’s possession, but only if the
combination itself and its principles of operation are in the public domain or in the Receiving Party’s possession. 
  

	1.4	“Control,” “Controlled by” and other correlatives meancontrol by Celexion in the Field of Use by ownership or license, provided that DNP Green shall
be responsible for all compensation to any future licensors (for licenses entered into after the Effective Date) in consideration for sublicensing rights for Celexionto grant the licenses to DNP Green granted in this Agreementthat DNP Green has
approved prior to its being agreed by Celexion and such Licensors. 

  

	1.5	“Effective Date” means September 25, 2010. 

  

	1.6	“Field of Use” means the production of the Products, either (i) as the [***] in the Licensed Intellectual Property, or (ii) through the [***]
in the Licensed Intellectual Property. 

  

	1.7	 “Licensed Intellectual Property” means, subject to the terms and conditions of this Agreement, (a) the Celexion Patent [***],
(b)the otherCelexion Patent Rights, (c) the Work Plan Intellectual Property owned by Celexion, and (d) all know-how, trade secrets, systems, copyrighted materials, software, database rights, technology, Confidential

  

					
	 Celexion and DNP
	 	2	  	Confidential

 * Confidential
treatment requested 

	 	
Information of Celexion not included in the foregoing and any other present or future intellectual property right, other than trademarks, wherever in the world enjoyable, in each case (a), (b),
(c) and (d) Controlled by Celexion,and necessary for the development, piloting, scale-up and otherexercise of the license rights granted in Section 2.1, according to the terms hereof, but excluding any rights that have no application
in the Field of Use. 

  

	1.8	“Product(s)” means all or any ofthe products listed in Schedule B, which practice, use or constitute, or which but for the license in this Agreement would
infringe, Licensed Intellectual Property or DNP Green Improvements. 

  

	1.9	“Successful Completion” and its correlatives mean the criteria for successful completion of each Work Plan Phase as set forth in the Work Plan.

  

	1.10 	“Transfer Date” means the date on which each Phase of the Work Plan has been Successfully Completed. 

 

	1.11 	“Work Plan Intellectual Property” means to the extent developed or invented solely by Celexion or DNP Green, or jointly by Celexion and DNP Green, in the
performance of the Work Plan: (a) all inventions and discoveries whether or not patented or patentable, and any Celexion Patent Rights claiming such inventions and discoveries, and (b) all know-how, trade secrets, systems, copyrighted
materials, software, database rights, technology, Confidential Information of Celexion not included in the foregoing and any other present or future intellectual property right, other than trademarks, wherever in the world enjoyable in each case
(a) and (b) owned or controlled by, or licensed to Celexion, in which Celexion has sufficient rights to grant the rights and licenses granted in this Agreement to DNP Green, and necessary for the development, piloting, scale-up and
commercially viable exercise of the license rights granted in Section 2.1, according to the terms hereof. 

 ARTICLE II
LICENSE GRANT; COLLABORATION R&D 
 License 

 

	2.1	Subject to the terms and conditions of this Agreement, Celexion hereby grants to DNP Green an exclusive, worldwide, royalty bearing license in the Field of Use, with
the right to sublicense, under and to the Licensed Intellectual Property, to develop, have developed, make, have made, use, sell or otherwise transfer, offer for sale, and/or import any Product, provided that any sublicensee has agreed in writing to
be bound by terms no less strict than the terms of this Agreement and must be in compliance with Sections 2.13 and 2.14. 

  

	2.2	There are no rights or licenses implied for either Party to practice the Confidential Information or intellectual property of the other Party, except as expressly
provided and granted in this Agreement. 

  

					
	 Celexion and DNP
	 	3	  	Confidential

 * Confidential
treatment requested 

 Experimental Work to be made by Celexion 

 

	2.3	During [***] following the Effective Date, with an option to extend such period by mutual agreement between Celexion and DNP Green, Celexion will carry out [***] work
relating to [***] in connection with the Licensed Intellectual Property, as more fully described in the work plan attached hereto as Schedule C (the “Work Plan”) and in accordance with the level of FTE effort described in such Schedule C
and Section 2.6. 

  

	2.4	Celexion will provide informed personnel trained in accordance with accepted industry practices, and Celexion will be solely responsible for the negligent acts, errors
and omissions of its employees, subcontractors, and agents and for any other person performing services in connection with the Work Plan. 

  

	2.5	Celexion will perform the Work Plan in a workmanlike manner with reasonable skill and care ordinarily exercised by members of the profession practicing under similar
conditions and in accordance with accepted industry practices and professional guidelines. 

  

	2.6	DNP Green shall pay Celexion [***] per full-time equivalent (FTE) person (calculated on a annual basis) to perform the Work Plan, and Celexion will make available up to
[***] FTE persons to perform the work as outlined in the Work Plan. 

  

	2.7	Celexion shall cover ordinary and customary lab supplies out of the FTE rate. Any lab expenses that are not ordinary and/or customary but are incurred as part of the
Work Plan will be paid by DNP Green. 

  

	2.8	Celexion shall submit to DNP Green a monthly invoice for costs owed by DNP Green, accompanied by a report summarizing Celexion’s activities in relation to actual
hours worked and expenses incurred. 

  

	2.9	DNP Green will pay Celexion’s costs within thirty (30) days of receipt of invoice and supporting documentation. 

 

	2.10 	DNP Green shall have the right to audit Celexion time sheets from time to time upon fifteen (15) days notice. Such audit shall occur during reasonable business
hours by an independent third party agreed to by both parties, who shall be under written obligations of confidentiality to Celexion at least as stringent as those herein. 

Sublicensing 
  

	2.11 	DNP Green shall promptly notify Celexion of the identity of any entity to which it has sublicensed the Licensed Intellectual Property under the rights granted in
Section 2.1 and subject to this Article II and provide a copy of the sublicense to Celexion, with financial and confidential information redacted that does not relate to this Agreement. DNP Green shall incorporate terms and conditions into its
sublicense agreements sufficient to enable DNP Green to comply with this Agreement, including without limitation Article VI and Section 8.6. Celexion shall be a third party beneficiary of each sublicense, with the right to enforce the terms
thereof in the event DNP Green does not enforce its rights. 

  

					
	 Celexion and DNP
	 	4	  	Confidential

 * Confidential
treatment requested 

	2.12 	Effective on the date this Agreement is terminated for any reason prior to the end of its term (the “Termination Date”), and provided that any DNP Green
sublicensee is not then in default under the terms of the sublicense to which it is a party, then DNP Green hereby assigns and agrees to assign to Celexion those of its rights, title and interest under any such sublicense that are in effect on the
Termination Date that relate to the license granted herein, including the right for Celexion to receive the portion of the income from the sublicense that relates to the license provided herein that would have been due DNP Green had this Agreement
not been terminated, and Celexion undertakes to respect the terms of any such sublicense as though Celexion itself had contracted directly with such sublicensee solely with respect to the Licensed Intellectual Property, in accordance with the terms
of any such sublicense so long as any such sublicensee is in full compliance with the terms of its sublicense; provided further that: 

 (i) such sublicensee must agree in a writing delivered to Celexion within thirty (30) days after the Termination Date to be bound to Celexion (a) for all obligations which relate to the Licensed
Intellectual Property, including the payment of royalties, specified in the sublicense agreement, and (b) IV, VI and X, and Sections 2.14 (pro rata with other sublicensees), 3.6, 8.1, 8.4, 8.5, 8.6, 8.8, 8.9, and 9.4 of this Agreement; and

 (ii) Celexion shall not assume any obligation of DNP Green to such sublicensee different from or beyond its obligations to DNP
Green sublicensees in this Agreement. 
 Prosecution and maintenance of patent rights 

 

	2.13 	Celexion shall use reasonable efforts to prosecute any and all patent application(s) included in the Celexion Patent [***], for so long as DNP Green is in compliance
with Section 2.14, and thereafter in its sole discretion. 

  

	2.14 	DNP Green will reimburse Celexion for reasonable patent costs (including without limitation attorneys’ fees and filing and maintenance costs) associated with the
preparation, filing, prosecution, translation and maintenance of the Celexion Patent Rights in the United States and in other designated jurisdictions as mutually agreed per Section 2.15. Celexion will provide an invoice in reasonable detail,
and DNP Green shall reimburse such costs within thirty (30) days thereafter. Notwithstanding the preceding, the Parties agree that significant expenses related to the prosecution of claims outside of the Field of Use shall be borne by Celexion.

  

	2.15 	Celexion shall use reasonable efforts to obtain patents for all patent applications incorporated in the Celexion Patent [***] and to maintain said Celexion Patent
[***], for so long as DNP Green is in compliance with Section 2.14, and thereafter in its sole discretion. The Parties agree to mutually establish a list of countries in which to file national entries for the Celexion Patent [***].

  

					
	 Celexion and DNP
	 	5	  	Confidential

 * Confidential
treatment requested 

 ARTICLE III PAYMENTS AND DILIGENCE 

Up-Front and Annual Payments 
  

	3.1	DNP Green shall make the following nonrefundable payments to Celexion: 

  

	 	3.1.1	a payment of [***], at the Effective Date; 

  

	 	3.1.2	a payment of [***], on the [***] of the Effective Date; 

  

	 	3.1.3	prior to the earlier of the date of [***], an annual payment of [***], the first of such payment being due on the [***] of the Effective Date, and annually thereafter;

  

	 	3.1.4	a payment of [***], on [***]; and 

  

	 	3.1.5	an annual payment of [***] on each anniversary of the Effective Date following [***]. 

Milestone Payments 
  

	3.2	DNP Green shall make the following milestone payments to Celexion within thirty (30) days of achieving each of the milestones summarized below, which payments
shall not be refundable in any event: 

  

	 	3.2.1	a payment of [***], when Phase I and Phase II of the Work Plan have been Successfully Completed; and a payment of [***] when Phase III of the Work Plan has been
Successfully Completed. 

  

	 	3.2.2	a payment of [***], when a Product developed under this Agreement achieves [***]; 

 

	 	3.2.3	a payment of [***], when [***]. 

  

					
	 Celexion and DNP
	 	6	  	Confidential

 * Confidential
treatment requested 

	 	3.2.4	a payment of [***], on the date when the [***]; 

  

	 	3.2.5	a payment of [***], at the [***]. 

 Royalty Payments 
  

	3.3	In further consideration of the license granted in Article II, DNP Green shall pay Celexion the following amounts: 

 

	 	3.3.1	[***], a royalty rate of [***] on the portion of all royalty and other payments and on the cash equivalent ofthe fair market value of non-cash compensation received by
DNP Green from any sublicensee that relate to the Products, Licensed Intellectual Property and/or the DNP Green Improvements; and 

  

	 	3.3.2	[***], DNP Green will pay Celexion a royalty rate of [***] of net sales of such Products produced and sold (being the gross sales of such Products less allowed product
returns and reasonable product allowances consistent with usual industry practices, all as determined according to standard accounting practices) and on the cash equivalent of the fair market value of non-cash compensation. If a Product shall
otherwise be distributed or invoiced for a discounted price substantially lower than customary in the trade or distributed at no cost, to Affiliates of Licensee or otherwise, net sales shall be based on the average amount billed for such Products
during the applicable reporting period. 

 Third Party Claims and Reduction of Payments 

 

	3.4	If the practice of the Celexion Patent Rightsgranted pursuant to this Agreement in the Field of Use results in a third party bringing a claim, suit or proceeding
alleging patent infringement against DNP Green, DNP Green shall promptly notify Celexion in writing setting forth the facts of such claim in reasonable detail. 

 

	3.5	If it is impossible for DNP Green to practice the Celexion Patent Rightsgranted pursuant to this Agreement in the Field of Use without obtaining a license from a third
party asserting an infringement claim pursuant to Section 3.4, and DNP Green takes a license directly from the third party alleging infringement, Celexion shall reduce the payment obligations set forth in Section 3.3 by an amount equal to
[***] of the amounts payable to such third party in exchange for a license to the asserted patent that allows DNP Green to practice the Celexion Patent Rights granted pursuant to this Agreement, provided that in no event shall the payment reductions
set forth immediately above be greater than [***] of the payments otherwise due to Celexion in any calendar quarter. 

  

					
	 Celexion and DNP
	 	7	  	Confidential

 * Confidential
treatment requested 

	3.6	All payments due hereunder shall be paid in full, without deduction of withholding taxes or other fees that may be imposed by any government, except as otherwise
provided in the definition of net sales in Section 3.3.2. 

 Diligence 

 

	3.7	(a) DNP Greenshall use commercially reasonable efforts to develop Products and shall continue commercially reasonable development and marketing efforts of Products in
the Field of Use throughout the term of this Agreement. 

 (b) In addition: 

[***] 
 provided, however,
Licensee will not be in breach of Section 3.7(b) for failure to meet any milestone as a result of technical or manufacturing difficulties beyond Licensee’s reasonable control. In the event of technical or manufacturing difficulties
beyond Licensee’s reasonable control, Licensee will notify Celexion if it anticipates missing a milestone date(s), and the parties will negotiate a milestone(s) extension in good faith. If the parties are unable to agree on a milestone
extension or other settlement within ninety (90) days, either party may send notice of a dispute pursuant to Section 10.2. If neither party sends such a notice within the allotted time period in Section 10.2, either party may elect to
terminate this Agreement effective on notice. 

  

					
	 Celexion and DNP
	 	8	  	Confidential

 * Confidential
treatment requested 

 ARTICLE IV PAYMENT REPORTS 

 

	4.1	Subsequent to the initial payment of Section 3.1.1, DNP Green shall report in writing to Celexion, within thirty (30) days after the end of each calendar
quarterafter the Effective Date, the royalty payments and net sales of Products subject to royalty payments pursuant to Article III during that calendar quarter. If there were no such royalties or sales, a report nevertheless shall be submitted so
stating. Payment shall be submitted to Celexion concurrent with submission of the report. Unless Celexion notifies DNP Green otherwise, the report shall be submitted to: 

Celexion, LLC 

[***] 
 A copy of
the report shall be submitted concurrently to the office receiving notices for Celexion in accordance with Article V. 
  

	4.2	Unless Celexion notifies DNP Green otherwise, all payments due to Celexion hereunder shall be in U.S. Dollars and shall be submitted by wire transfer to:

 [***] 
 In the event that royalties accrue in a currency other than U.S. Dollars, the royalties shall be converted into U.S. Dollars at the closing buying rate of the bank abovementioned in effect on the last
business day of the accounting period for which payment is due; provided, however, Celexion may notify Licensee, for future payments, of (i) another published currency conversion standard that shall apply, or (ii) wire transfer
instructions for payment of royalties in the currency in which the royalties accrued. 
  

	4.3	If any payment due hereunder is not paid when due, the unpaid amount shall bear interest at an annual rate of the greater of two points above the prime rate then in
effect at the above bank or five per cent (5 %), until paid. The payment of such interest shall not foreclose Celexion from exercising any other rights it may have under this Agreement or in law or equity as a consequence of the lateness of any
payment. 

  

					
	 Celexion and DNP
	 	9	  	Confidential

 * Confidential
treatment requested 

	4.4	DNP Green, its Affiliates and the sublicensees shall keep adequate records in sufficient detail to enable the royalties payable to Celexion hereunder, and other
compliance with this Agreement, to be determined for at least five (5) years following the date on which a royalty report is due. Upon fifteen (15) days notice, the records may be inspected, and employees involved in the sale of Products
developed under this Agreement may be interviewed during normal business hours by an independent auditor appointed by Celexion for that purpose. The independent auditor shall be bound by terms of confidentiality and non-use at least as stringent as
those contained herein. The independent auditor shall report to Celexion only the amount of royalties payable hereunder except in the event that the auditor deems there has been underpayment or other noncompliance, in which event the auditor may
report to Celexion and DNP Green details concerning such underpayment or other noncompliance. DNP Green shall immediately pay the underpayment and reimburse Celexion for the audit expense if the audit reports a discrepancy of five percent
(5%) or more in underreported royalties. 

 ARTICLE V NOTICES 

 

	5.1	All notices pursuant to the Agreement shall be in writing and sent by facsimile or overnight or two-day courier, and deemed received on the date of confirmation of
transmission of facsimile or courier receipt, directed as follows, unless the Party receiving notice notifies the other Party of a different recipient for the notice: 

If to Celexion: 

Celexion, LLC 

[***] 
 If to
DNP Green: 
 DNP Green Technology, Inc. 

1250 Rene-Levesque West, Suite 4110 

Montreal, Quebec, Canada 
 H3B 4W8 
 Attn: Mr. Jean-François Huc, President

 E-Mail : [***] 
 Facsimile : (514) 844-5836 
 With a copy to : 

Boivin Desbiens Senecal, g.p. 
 [***] 

  

					
	 Celexion and DNP
	 	10	  	Confidential

 * Confidential
treatment requested 

 ARTICLE VI CONFIDENTIAL INFORMATION 

 

	6.1	Confidential Information disclosed by a Disclosing Party to a Receiving Party shall be maintained in strict confidence by the Receiving Party, and not used for any
purpose other than those authorized by this Agreementfor the term of this Agreement and for [***] after termination, if terminated early, or the term of this Agreement and for [***] after expiration; provided that a Receiving Party may, in
connection with the exercise of its rights hereunder, disclose the Confidential Information to third parties who have need to know in connection with the purpose pertained hereto and that agree in writing to be bound by terms of confidentiality and
non-use at least as stringent as those contained herein. Each Receiving Party shall take precautions as it normally takes with its own confidential and proprietary information of similar nature to prevent disclosure to third parties, but no less
than reasonable precautions. Each Receiving Party shall be responsible for the breach of this Article VI by the Receiving Party, its Affiliates, subcontractors and agents. 

 

	6.2	A Receiving Party agrees not to disclose Confidential Information received from a Disclosing Party to any of its employees other than those who have need to know in
connection with the purpose pertained hereto, and any employee to whom disclosure is made shall be made aware of the restrictions herein provided. 

  

	6.3	All Confidential Information disclosed by either Party to the other hereunder shall be maintained in strict confidence, and not used or disclosed to any third party by
the Receiving Party except as expressly authorized by provisions of this Agreement, for a period corresponding to the term of this Agreement and for [***] after termination, if terminated early, or the term of this Agreement and for [***] after
expiration. 

  

	6.4	A Receiving Party may disclose Confidential Information to the extent required to be disclosed pursuant to law or regulation, judicial or administrative process;
provided that prior to any disclosure, the Receiving Party shall (a) assert the confidential nature of the Confidential Information to the authority; (b) immediately notify the Disclosing Party in writing; and (c) cooperate fully with
the Disclosing Party in protecting against disclosure or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality. 

 

	6.5	The Parties acknowledge and agree that because the breach or threatened breach of this Article VI would result in immediate and irreparable injury, each Disclosing
Party shall be entitled, without posting of bond or other security, to temporary and permanent injunctive and other equitable relief restraining the Receiving Party from activities constituting a breach or threatened breach of this Article VI to the
fullest extent allowed by law. Such relief shall not limit a Disclosing Party’s right to seek all other remedies available at law or in equity, including without limitation, the recovery of damages. 

  

					
	 Celexion and DNP
	 	11	  	Confidential

 * Confidential
treatment requested 

	6.6	As of the Effective Date, the Confidential Disclosure and Non-Use Agreement between the Parties dated November 6, 2009 (the “Confidentiality Agreement”)
is hereby superseded by this Agreement, except as to confidential information and materials provided thereunder prior to the Effective Date of this Agreement or otherwise not subject to this Agreement. 

ARTICLE VII IMPROVEMENTS 
  

	7.1	During the term of this Agreement, DNP Green shall have [***], at its cost, to create “[***].” “[***]” mean [***]. 

 

	7.2	The Parties acknowledge and agree that DNP Green shall own all rights, title, and interest in and to [***]. 

 

	7.3	The Parties also acknowledge and agree that Celexion shall own all rights, title, and interest in and to [***]. 

 

	7.4	DNP Green shall have the right at its own discretion to secure intellectual property protection in any of the [***]. 

 

	7.5	Licensee shall promptly disclose to Celexion any DNP Green Improvements. Subject to the terms and conditions of this Agreement, Licensee hereby grants to Celexion and
its Affiliates [***] license [***], with the right to grant and authorize the grant of sublicenses at any tier, under Licensee’s intellectual propertyrights to make, have made, use, offer for sale, sell, import and otherwise dispose of products
and practice processes, and to practice processes and use, copy, modify and, if permitted under Article VI (Confidential Information), distribute information [***]. 

 

	7.6	Each Party shall promptly disclose to the other Party any Work Plan Intellectual Property. The Parties shall evaluate jointly whether trade secret or patent protection
is appropriate to protect any Work Plan Intellectual Property jointly invented by one or more employees of Celexion and by one or more employees of DNP Green. DNP Green agrees that [***], without Celexion’s express prior written consent and
subject to the terms of this Agreement. In the event that one or both of the Parties believe that patent protection is appropriate, the Parties shall cooperate in the preparation, filing and prosecution of any such patent application claiming [***].

  

					
	 Celexion and DNP
	 	12	  	Confidential

 * Confidential
treatment requested 

 ARTICLE VIII REPRESENTATIONS AND LIMITATIONS 

 

	8.1	WHILE IT IS EXPECTED THAT THE RIGHTS PROVIDED BY CELEXION UNDER THIS AGREEMENT WILL BE USEFUL TO DNP GREEN TO MAKE PRODUCTS ON A COMMERCIAL SCALE, CELEXION DOES NOT
WARRANT OR GUARANTEE THAT SUCH RESULTS WILL BE OBTAINED. CELEXION SHALL NOT BE LIABLE TO DNP GREEN, ITS AFFILIATES OR ANY SUBLICENSEES BECAUSE OF ANY FAILURE IN ITS OPERATIONS OR OF THE LICENSED INTELLECTUAL PROPERTY TO ACHIEVE THE DESIRED RESULTS.
THERE ARE NO OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE, OTHER THAN THOSE EXPRESSLY EXTENDED IN THIS ARTICLE VIII. 

 

	8.2	To Celexion’s knowledge and belief, but without obligation of inquiry, DNP Green may exercise its rights to practice the Celexion Patent Rights in the Field of Use
under the license granted in Section 2.1 of this Agreement without infringing patent(s) owned by any third partybecauseCelexion has received no third party notice of infringement. In the event that any claims or legal proceedings are brought by
any third party alleging that the use of the Licensed Intellectual Property by DNP Green, any of its Affiliates or any of its sublicensees would infringe patent rights or other third party intellectual property rights, Celexion shall provide
technical advice and assistance (as requested) to effectively aid DNP Green in defending such allegation of infringement. 

  

	8.3	In the event that either Party becomes aware that a third party is infringing any Licensed Intellectual Property in the Field of Use, it shall immediately inform the
other Party and provide such information in its possession concerning the alleged infringement. Celexion may, but shall not be obligated to, take steps to abate the infringement at its own expense. If Celexion does not elect to so proceed, DNP Green
may elect to bring suit, in its own name and at its own expense, against the alleged infringer solely in the Field of Use. The Party bringing suit shall receive any recoveriesafter reimbursement of the legal fees and expenses of each Party. Any
recoveries by DNP Green shall be deemed to be subject to royalty payments under Section 3.3.1 as if received by a sublicensee. 

  

	8.4	TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW AND EXCEPT FOR BREACH BY EITHER PARTY, ITS AFFILIATES OR SUBLICENSEES OF ANY LICENSE GRANTED TO SUCH PARTY IN THIS
AGREEMENT, BREACH BY EITHER PARTY, ITS AFFILIATES OR SUBLICENSEES OF ARTICLE VI (CONFIDENTIAL INFORMATION), OR DAMAGES SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 8, NEITHER PARTY SHALL BE RESPONSIBLE TO THE OTHER FOR SPECIAL, INCIDENTAL,
EXEMPLARY, OR CONSEQUENTIAL DAMAGES THAT MAY BE INCURRED PURSUANT TO THIS AGREEMENT OR PERFORMANCE HEREUNDER. 

  

	8.5	WHILE IT IS BELIEVED THAT THE ORDINARY AND ANTICIPATED USE OF THE LICENSED INTELLECTUAL PROPERTY, AND PRODUCTS MADE THEREBY, WILL NOT RESULT IN SAFETY OR HEALTH HAZARDS
TO WORKERS OR TO PURCHASERS OF SUCH PRODUCTS, CELEXION DOES NOT WARRANT OR GUARANTEE AGAINST SUCH HEALTH OR SAFETY HAZARDS. 

  

					
	 Celexion and DNP
	 	13	  	Confidential

 * Confidential
treatment requested 

	8.6	DNP GREEN HAS SOLE DISCRETION AND RESPONSIBILITY FOR ITS DESIGN, MANUFACTURE, AND SALE OF PRODUCTS PURSUANT TO THIS AGREEMENT. ACCORDINGLY, DNP GREEN SHALL INDEMNIFY,
DEFEND, AND HOLD CELEXION AND ITS AFFILIATES, AND THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, AGENTS AND CONSULTANTS, (COLLECTIVELY, “INDEMNITIES”) HARMLESS FROM AND AGAINST ANY AND ALL CLAIMS, SUITS, OBLIGATIONS, CAUSES OF ACTION,
LIABILITY, COSTS AND DAMAGES (INCLUDING, WITHOUT LIMITATION, ATTORNEY FEES AND COURT COSTS), BASED UPON, ARISING OUT OF, OR RELATED TO: INJURIES TO PERSONS (INCLUDING DEATH) OR PROPERTY (INCLUDING, WITHOUT LIMITATION, LOSS OF USE), PRODUCT LIABILITY
CLAIMS, CLAIMS FOR DAMAGE TO THE ENVIRONMENT, AND THIRD PARTY CLAIMS DUE TO THE BREACH OF ANY OF ITS REPRESENTATIONS, COVENANTS AND AGREEMENTS CONTAINED IN THIS AGREEMENT (COLLECTIVELY, “LIABILITIES”), WHATEVER THE CAUSE MAY BE, BASED
UPON, ARISING OUT OF, OR RELATED TO THE ACTS OR OMISSIONS OF DNP GREEN AND ITS AFFILIATES AND/OR ANY OF THEIR EMPLOYEES, OFFICERS, EMPLOYEES, SUBCONTRACTORS AND CONSULTANTS OR OTHER PERSONS ACTING ON THEIR BEHALF OR UNDER THEIR CONTROL, IN
CONNECTION WITH DNP GREEN’S EXECUTION, DELIVERY AND PERFORMANCE OF, OR BREACH OR FAILURE TO PERFORM, THIS AGREEMENT, EXCEPT TO THE EXTENT THAT SUCH LIABILITIES ARE ESTABLISHED IN A COURT OF LAW TO HAVE BEEN CAUSED BY THE GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT ON THE PART OF ANY OF THE INDEMNITIES. 

  

	8.7	CELEXION AGREES TO DEFEND, INDEMNIFY, AND HOLD DNP GREEN, ITS AFFILIATES AND THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, HARMLESS FROM AND AGAINST ANY
AND ALL OUT-OF-POCKET COSTS, DAMAGES AND LOSSES (INCLUDING, WITHOUT LIMITATION, REASONABLE ATTORNEYS’ FEES AND COSTS) ARISING OUT OF OR RESULTING FROM THIRD PARTY CLAIMS DUE TO THE BREACH BY CELEXION OF ANY OF ITS REPRESENTATIONS, COVENANTS AND
AGREEMENTS CONTAINED IN THIS AGREEMENT, EXCEPT TO THE EXTENT THAT SUCH LIABILITIES ARE ESTABLISHED IN A COURT OF LAW TO HAVE BEEN CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF ANY OF SUCH INDEMNITIES. 

 

	8.8	The respective indemnitee shall notify the indemnifying Party within a reasonable period of time in writing of any claim, cooperate in the defense or settlement of such
claim as reasonably requested by the indemnifying Party, at the indemnifying Party’s expense, and tender the indemnifying Party with the sole control of the defense and all related settlement negotiations, although the indemnitee may be
represented by separate counsel at its expense. 

  

					
	 Celexion and DNP
	 	14	  	Confidential

 * Confidential
treatment requested 

	8.9	Nothing in this Agreement will be construed to limit either Party’s remedies for use of intellectual property rights outside the uses expressly permitted in this
Agreement. 

 ARTICLE IX TERM 
  

	9.1	The term of this Agreement shall commence on the Effective Date and continue in effect until [***], or until [***], whichever shall later occur, unless earlier
terminated in accordance with this Article. 

  

	9.2	DNP Green may terminate this Agreement at any time, and for any reason whatsoever, by providing Celexion with ninety (90) days advance written notice of
termination, along with payment of any amounts then outstanding. 

  

	9.3	Celexion may elect to provide DNP Green with thirty (30) days advance written notice of termination in the event that DNP Green material breaches this Agreement.
If DNP Green shall not have cured any such material breach within such thirty-day notice period, this Agreement shall terminate on the last day of such notice period. 

 

	9.4	Termination shall not affect the rights and obligations of either Party incurred prior to termination. The following Articles and Sections shall survive termination: I,
2.12, 4.3, 4.4, 5.1, VI, 7.2, 7.3, 7.4, 7.5, 7.6, 8.1, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.4, 9.5, and X. Upon termination, each Party shall return Confidential Information of the other Party, or destroy it, as the Disclosing Party shall instruct, and
cease any use of Confidential Information of the other Party, except as otherwise provided in Section 9.5. 

  

	9.5	In the event this Agreement is terminated before its expiry for any reason except in the event of a breach by Celexion or a breach by DNP Green of any of its
obligations listed at subsection 3.7 (b), DNP Green shall grant and hereby grants Celexion a royalty-free non-exclusive license to all DNP Green Improvements in the Field of Use, with the right to sub-license the DNP Green Improvements to third
parties. In the event that this Agreement is terminated due to a breach by DNP Green of any of its obligations listed at subsection 3.7 (b), within thirty (30) days after the effective date of termination, Celexion and DNP Green shall convene
to negotiate in good faith the commercially reasonable terms for a license to the DNP Green Improvements, solely to the extent it is required for Celexion, its Affiliates and sublicensees and their respective customers to practice the Licensed
Intellectual Property without infringing on patents or patent applications that result from the DNP Green Improvements. 

  

					
	 Celexion and DNP
	 	15	  	Confidential

 * Confidential
treatment requested 

 ARTICLE X MISCELLANEOUS 

 

	10.1 	The validity, interpretation and performance of this Agreement shall be governed and construed in accordance with the laws of the State of Delaware, without regard to
the conflict of law principles thereof. 

  

	10.2 	Any dispute hereunder shall be referred to senior management of the Parties for amicable settlement. If the Parties still are unable to agree within thirty
(30) days after referral of the dispute to senior management, they shall either: if mutually agreed, endeavor to resolve the dispute through a dispute resolution process reasonably selected for the dispute in question,or either Party may seek
remedy of a dispute in a court of law. 

  

	10.3 	This Agreement may be assigned or transferred by a Party to such entity that is the successor to substantially all of its equity or those business assets of the Party
to which this Agreement applies (“Successor”), provided that the Party gives written notice thereof to the other Party within a reasonable time and such successor agrees in writing to abide by the terms and conditions hereof within ten
(10) days after such assignment or transfer. Either Party may delegate performance hereunder, in whole or in part, to an Affiliate(s), but shall remain responsible for performance of its obligations hereunder and for the performance,
nonperformance, negligence, omission and acts of its Affiliates. Neither Party may otherwise assign, transfer or delegate this Agreement in whole or in part, without the prior written consent of the other Party. Notwithstanding anything to the
contrary in this Agreement, neither Party shall have any right or license whatsoever to any intellectual property rights, information or technology owned or controlled by an entity which becomes a Successor of the other Party hereunder (or any
subsequent Successor) and which was owned or controlled by such Successor prior to its becoming a Successor. Subject to the foregoing, this Agreement shall inure to the benefit of and be binding upon the Parties and their Successors.

  

	10.4 	The Parties shall abide by the laws and regulations of the United States, including, without limitation, Export Control and related regulations that pertain to the
export of technology. 

  

	10.5 	Each Party shall remain an independent contractor. Nothing herein shall be construed as creating an agency or joint venture relationship between the Parties.

  

	10.6 	This Agreement constitutes the entire agreement between the Parties concerning the subject matter contained herein. No representation or other affirmation of fact,
whether made by a Party’s employees, consultants, subcontractors or agents or otherwise, which is not contained in this Agreement will be deemed to be a warranty by such Party for any purposeor give rise to any liability of such Party
whatsoever. Any modifications or waivers shall be in writing, duly signed by both Parties. 

  

	10.7 	Neither party shall be responsible to the other for delay or failure in performance of any of the obligations imposed by this Agreement, provided such delay or failure
shall be occasioned by a cause beyond the control of and without the fault or negligence of such party, including fire, flood, explosion, lightning, windstorm, earthquake, subsidence of soil, discontinuity in the supply of power, court order or
governmental interference, civil commotion, riot, war, strikes, labor disturbances, transportation difficulties or labor shortage. Notwithstanding the aforesaid, if as a result either party fails to a substantial extent for at least three
(3) months to fulfill any of its obligations under this Agreement, the other party may terminate the Agreement upon thirty (30) days advance written notice of termination. 

  

					
	 Celexion and DNP
	 	16	  	Confidential

 * Confidential
treatment requested 

	10.7 	The waiver of performance of any of the provisions of this Agreement shall not be construed as a waiver of subsequent obligations to perform the same or different
provisions. Should any provision of this Agreement be held invalid, unenforceable or void for any reason, the remaining provisions shall remain in full force and effect. The headings are for convenience only and shall not be used in
construing this Agreement. 

  

	10.8 	Each Party shall execute and deliver such further assignments and other instruments and do such further reasonable acts and things as reasonably may be required to
carry out the intent and purpose of this Agreement. 

  

	10.9 	Licensee agrees to mark the Products sold in the United States with all applicable United States patent numbers in accordance with applicable United States patent Law.
All Products shipped to or sold in other countries shall be marked in such a manner as to conform with the patent laws and practice of the country of manufacture or sale. 

 

	10.10 	During the term of this Agreement and for a period of twelve (12) months thereafter, each Party agrees that neither it nor any of its Affiliates shall recruit,
solicit or induce any employee of the other Party to terminate his or her employment with the other party. In the event that either Party violates the above restriction and thereafter hires or engages the employee, such Party shall be liable for the
greater of (i) actual damages incurred as a result of the violation or (ii) liquidated damages in the amount of three months base salary of the employee as of the date of separation of employment. Such damages shall be in addition to and
not in lieu of any and all other equitable or legal remedies available including injunctive relief. 

  

	10.11 	If either Party would like to issue a press release at any time, it shall contact the other Party, and the Parties shall mutually agree on the content of the press
release. 

  

	10.12 	This Agreement may be executed in counterparts, each of which shall be deemed an original with all such counterparts together constituting one document. A signature
transmitted via facsimile or electronic pdf shall be deemed to be and shall be as effective as an original signature upon confirmation of transmission. 

  

					
	 Celexion and DNP
	 	17	  	Confidential

 * Confidential
treatment requested 

 IN WITNESS WHEREOF, the Parties have executed this Agreement. 

 

									
	CELEXION, LLC	 		 	DNP GREEN TECHNOLOGY, INC.
					
	Name:	 	/s/ [***]	 		 	Name:	 	/s/ Jim Millis
	Title:	 	CEO	 		 	Title:	 	CTO
					
	Date:	 	11/10/2010	 		 	Date:	 	7 November 2010

  

  

					
	 Celexion and DNP
	 	18	  	Confidential

 * Confidential
treatment requested 

 SCHEDULE A 
 List of the Celexion Patent [***]: 
 [***] 

  

					
	 Celexion and DNP
	 	19	  	Confidential

 * Confidential
treatment requested 

 SCHEDULE B 
 List of Products included in the Field of Use: 
 [***] 

  

					
	 Celexion and DNP
	 	20	  	Confidential

 * Confidential
treatment requested 

 SCHEDULE C 
 Work Plan 
 [*** 5 pages omitted.] 

  

					
	 Celexion and DNP
	 	21	  	Confidential

 * Confidential
treatment requestedJoint Venture Agreement

 Exhibit 10.38 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 EXECUTION COPY 

JOINT VENTURE AGREEMENT 
 by and among 
 BIOAMBER INC., 

BIOAMBER INTERNATIONAL S.à.r.l., 
 MITSUI & CO., LTD. 
 and 

BLUEWATER BIOCHEMICALS INC. 
 Dated November 2, 2011 

  
 tk-420278 

* Confidential treatment requested 

 JOINT VENTURE AGREEMENT 

THIS JOINT VENTURE AGREEMENT (this “Agreement”) is made and entered into as of the 2nd day of November, 2011, by
and among BioAmber Inc., a corporation organized under the laws of Delaware (“BioAmber”), BioAmber International S.à.r.l., a limited liability company organized under the laws of Luxembourg and a direct wholly owned
subsidiary of BioAmber (“BioAmber Lux”, and together with BioAmber, the “BioAmber Parties”), Mitsui & Co., Ltd., a corporation organized under the laws of Japan
(“Mitsui”), and Bluewater Biochemicals Inc., a corporation organized under the laws of Canada (the “Company”). 
 RECITALS 
 A. BioAmber Lux, Mitsui and the Company have
entered into respective Share Subscription Agreements, dated as of the date hereof (together, the “Subscription Agreements”), which provide, among other things, for the issuance by the Company, and the acquisition by BioAmber
Lux and Mitsui, of Shares representing [***], respectively, of the total outstanding Shares, on a fully diluted basis, on the terms and subject to the conditions set forth in the respective Subscription Agreements. 

B. Immediately after giving effect to the issuance of Shares to BioAmber Lux and Mitsui pursuant to the respective Subscription
Agreements, BioAmber Lux and Mitsui will collectively own all of the issued and outstanding Shares. 
 C. As a condition to the
issuance to, and the acquisition by, Mitsui and BioAmber Lux of their Shares pursuant to the respective Subscription Agreements, the parties agreed to enter into this Agreement to provide for certain matters relating to, among other things, the
management and operation of the Company. 
 NOW, THEREFORE, the parties agree as follows: 

 

	1.	DEFINITIONS AND INTERPRETATION; CLOSING IN ESCROW 

 1.1. Definitions. The following capitalized terms used herein shall have the following meanings unless the context otherwise requires: 

“Absent Shareholder” has the meaning set forth in Section 8.1.6. 

“Additional Contribution” has the meaning set forth in Section 5.2.1. 

“Additional Plants” has the meaning set forth in Section 4.1. 

“Affiliate” means, with respect to a specified Person, any other Person that directly, or indirectly through one
or more intermediaries, Controls or is Controlled by, or is under common Control with, such specified Person. 

“Agreement” has the meaning set forth in the preamble hereof. 

  
 - 1 -

 tk-420278 
 *
Confidential treatment requested 

 “Ancillary Agreements” means (a) the Technology License
Agreement, (b) the Trademark License Agreement, (c) the BioAmber Services Agreement, (d) the Mitsui Services Agreement, (e) the Assignment Agreement and (f) the Indemnification Agreement. 

“Applicable Law” means all applicable provisions of all (a) constitutions,
treaties, statutes, laws (including common law), rules, regulations, ordinances or codes; and (b) orders, decisions, judgments, awards or decrees, in each case of any Governmental Authority of the United States of America, Canada, Japan or
other applicable jurisdictions. 
 “Appraiser” has the meaning set forth in
Section 5.3.2(a). 
 “Arbitration Party” has the meaning set forth in
Section 22.2.1. 
 “Assignment Agreement” has the meaning set forth in
Section 16.4.4. 
 “BDO” means 1,4 Butanediol and Tetrahydrofuran (THF) produced from BSA using
the DuPont Technology. 
 “BioAmber” has the meaning set forth in the preamble hereof. 

“BioAmber IP” means all Intellectual Property Rights owned, co- or jointly owned, or held by BioAmber or its
Affiliates that are necessary, useful or otherwise related to the operation of the Business. 
 “BioAmber IP
Agreements” means any and all Contracts concerning Intellectual Property Rights that are necessary, useful or otherwise related to the operation of the Business to which BioAmber or any BioAmber Affiliate is a party or beneficiary, or
by which BioAmber or any BioAmber Affiliate, or any of its properties or assets, may be bound, including: (a) licenses of Intellectual Property Rights by BioAmber or any BioAmber Affiliate to any third party, (b) licenses of Intellectual
Property Rights by any third party to BioAmber or any BioAmber Affiliate, (c) Contracts between BioAmber or any BioAmber Affiliate and any third party relating to the transfer, development, maintenance or use of Intellectual Property Rights,
(d) covenants not to sue under or releases from any claim of damages for infringement, unauthorized use or disclosure, or misappropriation of any third party’s Intellectual Property Rights and (e) Consents, settlements, decrees,
orders, injunctions, judgments or rulings governing the use, validity or enforceability of Intellectual Property Rights. 

“BioAmber Lux” has the meaning set forth in the preamble hereof. 

“BioAmber Parties” has the meaning set forth in the preamble hereof. 

“BioAmber Right to Approve” has the meaning set forth in Section 8.1.2. 

“BioAmber Services Agreement” has the meaning set forth in Section 16.4.2. 

“BioAmber Technology” means the BioAmber IP and the Licensed IP. 

“BioAmber Triggering Event” has the meaning set forth in Section 11.2.1. 

  
 - 2 -

 tk-420278 
 *
Confidential treatment requested 

 “BioAmber Triggering Event Notice” has the meaning set forth in
Section 11.3.1. 
 “Board” means the board of directors of the Company. 

“Books and Records” has the meaning set forth in Section 9.2.1. 

“Book Value” means, with respect to a Share, [***]. 

“BSA” means bio-based succinic acid. 
 “Business” has the meaning set forth in Section 3.1. 
 “Change of Control” with respect to a Person means the occurrence of any of the following events: (a) the acquisition by any other Person or group of Persons, through any
transaction or series of related transactions, of Control of such Person; (b) such Person consolidates with, or merges with or into, another Entity, whether or not such Person is the surviving Entity of such transaction, unless immediately
after such consolidation or merger the Person or group of Persons who Controlled such Person immediately prior to the transaction Control such surviving Entity; or (c) a sale or other transfer of all or a substantially all of the assets or
business of such Person. In addition, a “Change of Control” with respect to BioAmber Lux (or any Permitted Transferee thereof) shall be deemed to occur if BioAmber sells or otherwise transfers all or substantially all of its BSA-related
assets or business (including the BioAmber Technology). 
 “Charter Documents” of any Person means such
Person’s articles of incorporation, certificate of formation, memorandum or articles of association, by-laws or equivalent governing or organizational documents. 
 “Closing Documents” has the meaning set forth in Section 1.2.6. 
 “Company” has the meaning set forth in the preamble hereof. 
 “Company Counsel” has the meaning set forth in Section 1.2.6. 
 “Company Valuation” has the meaning set forth in Section 5.3.2. 
 “Confidential Information” means all Trade Secrets and other confidential and/or proprietary information of a Person, including business, technical, or financial information
relating to the matters contemplated hereby, the terms or existence of this Agreement or other matters relating to the operation of the Business contemplated hereby. 
 “Consent” means any approval, consent, ratification, permission, waiver or authorization (including by or from any Governmental Authority) 

“Construction Budget and Schedule” has the meaning set forth in Section 3.3. 

  
 - 3 -

 tk-420278 
 *
Confidential treatment requested 

 “Contract” means any agreement, contract, consensual obligation,
promise, understanding, arrangement, commitment or undertaking of any nature (whether written or oral and whether express or implied), whether or not legally binding. 
 “Contribution Notice” has the meaning set forth in Section 5.2.1. 
 “Control” of a Person (and, with correlative meaning, “Controls” and “Controlled”) means (i) the ownership of a majority of the
voting securities of such Person or (ii) the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of Equity Securities, by Contract or
otherwise. 
 “Copyrights” means all copyrights and copyrightable works, and applications for
registration thereof, including all rights of authorship, publication, reproduction, distribution, performance and transformation and moral rights, together with all other interests accruing by reason of international copyright conventions.

 “Co-Sale Right” has the meaning set forth in Section 11.3.2. 

“Defaulting Shareholder” means a Shareholder in respect of whom an Event of Default has occurred and is
continuing. 
 “Default Option Exercise Notice” has the meaning set forth in Section 18.2.3.

 “Defending Party” has the meaning set forth in Section 22.2.5. 

“Director” means a member of the Board. 
 “Disclosing Party” has the meaning set forth in Section 23.14.1. 
 “Dispute” has the meaning set forth in Section 22.1. 
 “Dissolution Event” has the meaning set forth in Section 19.1. 
 “Dissolution Notice” has the meaning set forth in Section 19.1. 
 “Dollars” or “$” refers to lawful currency of Canada. 
 [***] 
 “Drag-Along Expiration Date” has the meaning set
forth in Section 11.2.1. 
 “Drag-Along Right” has the meaning set forth in
Section 11.2.1. 
 “Dupont” means E. I. du Pont de Nemours. 

“DuPont Technology” means all Intellectual Property Rights licensed or sublicensed by Dupont to BioAmber or a
BioAmber Affiliate that are necessary or useful to or otherwise used in connection with the production of BDO, including all Patents and other Intellectual Property Rights licensed to BioAmber S.A.S. under the License Agreement, dated as of
June 28, 2010, between DuPont and BioAmber S.A.S. 

  
 - 4 -

 tk-420278 
 *
Confidential treatment requested 

 “Encumber” and “Encumbrance” have the
respective meanings set forth in Section 10.2.1. 
 “Entity” means any corporation
(including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust or company (including any limited liability company or joint stock company). 

“EPC Contract” means the engineering, procurement and construction contract to be entered into between the
Company and the EPC Firm in respect of Phase I of the Initial Plant consisting of the construction of the initial phase of the Initial Plant having an initial annual capacity of 17,000 MT of BSA. 

“EPC Firm” means the engineering, procurement and construction firm retained by the Company for the construction
of the Initial Plant pursuant to the EPC Contract. 
 “Equity Securities” means, with
respect to any Person, such Person’s capital stock, issued share capital, membership interests, partnership interests, registered capital, joint venture or other ownership interests or any options, warrants or other securities that are directly
or indirectly convertible into, or exercisable or exchangeable for, such capital stock, issued share capital, membership interests, partnership interests, registered capital, joint venture or other ownership interests (whether or not such derivative
securities are issued by such Person). 
 “Escrow Release Time” has the meaning set forth in
Section 1.2.6. 
 “Event of Default” has the meaning set forth in
Section 18.1.1. 
 “Fair Market Value” means fair market value. 

“Financial Statements” means the financial statements of the Company. 

“Financial Year” means the financial or fiscal year of the Company, which shall end on December 31 of each
year. 
 “Financing Share Price” has the meaning set forth in Section 5.3.2. 

“First Disbursement” has the meaning set forth in Section 1.2.6. 

“Governmental Approval” means any: permit, license, certificate, concession, approval, consent, ratification,
permission, clearance, confirmation, exemption, waiver, franchise, certification, designation, rating, registration, variance, qualification, accreditation or authorization issued, granted, given or otherwise made available by any Governmental
Authority. 
 “Governmental Authority” means (a) any government or political subdivision thereof
(including any state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature); (b) any department, agency or instrumentality of any government or political subdivision thereof; (c) any court
or arbitral tribunal; and (d) the governing body of any securities exchange, in each case having competent jurisdiction. 

  
 - 5 -

 tk-420278 
 *
Confidential treatment requested 

 “Government Finance Agreements” has the meaning set forth in
Section 17.1.8. 
 “Hazardous Material” means any substance, chemical, compound, pollutant,
waste or other material that is listed, defined or otherwise identified as hazardous, toxic, reactive, infectious, carcinogecic, mutagenic or dangerous under any Applicable Law. 

“ICC” means the International Chamber of Commerce. 

“ICC Rules” has the meaning set forth in Section 22.2.1. 

“IFRS” means the international accounting standards or the international financial reporting standards prescribed
by the International Accounting Standards Board and its successors. 
 “Indemnification Agreement” has
the meaning set forth in Section 8.2.13. 
 “Initial Plant” has the meaning set forth in
Section 3.1. 
 “Initial Plant Site” has the meaning set forth in
Section 17.1.16. 
 “Intellectual Property Rights” means all right, title, and interest
arising from or in respect of any of the following, whether protected, created or arising under the laws of the United States or any other jurisdiction: (a) all Patents; (b) all Trademarks; (c) all Copyrights; (d) Trade Secrets
or Know-how; and (e) all rights, benefits, privileges, causes of action, and remedies relating to any of the foregoing, whether before or hereafter accrued, including the exclusive rights to apply for and maintain all registrations, renewals,
and extensions, to sue for all past, present, and future infringements, unauthorized uses or disclosures, or misappropriations of any rights relating thereto, and to settle and retain proceeds from any such actions. 

“Issuance Notice Period” has the meaning set forth in Section 14.3. 

“IPO” means an initial public offering of Equity Securities pursuant to a prospectus, an effective registration
statement, a listing agreement or otherwise in any jurisdiction. 
 “Joinder Agreement” has the meaning
set forth in Section 23.16. 
 “Know-how” means all title, right and interest in all Trade
Secrets, ideas, methods, concepts, proprietary techniques, processes, formulae, specifications, inventions and discoveries (whether patentable or unpatentable and whether or not reduced to practice), business and other methodologies, scientific,
technical, research, development, engineering and business information, and other know-how, including all Trade Secret rights arising under any law, including common law, state law, federal law or laws of foreign countries, other than Copyrights,
Patents and Trademarks. 
 “Lenders” means any third-party lenders of the Company. 

  
 - 6 -

 tk-420278 
 *
Confidential treatment requested 

 “Licensed IP” means any and all Intellectual Property Rights that
BioAmber or its Affiliates are licensed or otherwise permitted by other Persons to use under the BioAmber IP Agreements that are necessary, useful or otherwise related to the operation of the Business. 

“Loss” means any loss, damage, injury, decline in value, liability, claim, demand, settlement, judgment, award,
fine, penalty, tax, fee (including any attorney’s, accountant’s, expert’s or other advisor’s fees, costs and expenses), charge, cost (including any cost of investigation) or expense of any nature, whether or not involving a
third-party claim. 
 “Mitsui” has the meaning set forth in the preamble hereof. 

“Mitsui Maximum Commitment” has the meaning set forth in Section 5.1.5. 

“Mitsui Services Agreement” has the meaning set forth in Section 16.4.3. 

[***] 

“Offered Shares” has the meaning set forth in Section 11.1.1. 

“Offering Shareholder” has the meaning set forth in Section 11.1.1. 

“Offering Shareholder Terms” has the meaning specified in Section 11.1.4. 

“Offer Notice” has the meaning set forth in Section 11.1.2. 

“Operational Date” means the date on which (i) the physical facilities of the Initial Plant have been
constructed, installed, commissioned and become operational and (ii) the Initial Plant has had a period of ten (10) days of continuous operation. 
 “Oversubscription Rights” has the meaning set forth in Section 14.1. 
 “party” means any signatory to this Agreement and any Person that subsequently becomes a party to this Agreement as provided herein. 

“Patents” means all patent rights, title and interests in and to all letters patent and rights accorded under
patent law systems, utility models, and applications therefor, including continuations, divisionals, continuations-in-part, reissues, reexaminations, substitutions, renewals, and extensions thereof, foreign counterparts thereto, and patents issuing
thereon. 
 “PBS” means a polymer comprised primarily of residues of diacids and diols, wherein the
diacid component comprises at least 65% by mole of BSA and the diol component comprises at least 65% by mole of BDO. 

“Permitted Issuance” has the meaning set forth in Section 14.1. 

“Permitted Transferee” has the meaning set forth in Section 10.2.3. 

“Person” means any individual, Entity or Governmental Authority. 

  
 - 7 -

 tk-420278 
 *
Confidential treatment requested 

 “Petitioning Party” has the meaning set forth in
Section 22.2.5. 
 “Plant Manager” has the meaning set forth in
Section 8.1.2(f). 
 “Preemptive Rights” has the meaning set forth in
Section 14.1. 
 “Proceeding” means any action, suit, litigation, arbitration, proceeding
(including any civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or
heard at law or in equity or before any Governmental Authority or any arbitrator or arbitration panel. 
 “Proposed
Issuance” has the meaning set forth in Section 14.2. 
 “Proposed Recipient”
has the meaning set forth in Section 14.1. 
 “Pro Rata Share” means, with respect to a
Shareholder, the proportion that the number of Shares held by such Shareholder (together with any Permitted Transferee thereof) bears to the aggregate number of Shares held by all Shareholders. 

“Provisional Remedy” has the meaning set forth in Section 22.2.6. 

“PTT-MCC Biochem” means PTT MCC Biochem Ltd. 

“Receiving Party” has the meaning set forth in Section 23.14.1. 

“Registered IP Assets” means Patents, registered Trademarks, and registered Copyrights, including any pending
applications for any of the foregoing owned by BioAmber or any of its Affiliates. 
 “Release
Conditions” has the meaning set forth in Section 1.2.6. 
 “ROFO Exercise
Notice” has the meaning set forth in Section 11.1.3. 
 “Secretary” means the
secretary of the Company. 
 “Shareholder” means (i) BioAmber Lux, (ii) Mitsui or
(iii) any other Person who becomes a holder of Shares in accordance with the terms of this Agreement and executes a Joinder Agreement, in each case for so long as such Person remains a holder of any Shares. 

“Shares” means all ordinary shares in the share capital of the Company that may be authorized and issued from
time to time. 
 “Subscription Agreements” has the meaning set forth in the recitals hereof. 

“Supply Contracts” means the Contracts set forth in Schedule 16.5, as such Schedule may be amended from
time to time as provided herein. 

  
 - 8 -

 tk-420278 
 *
Confidential treatment requested 

 “Technology License Agreement” means that certain
Process and Technology License Agreement, dated as of the date hereof, among BioAmber, BioAmber Lux, as licensor, and the Company, as licensee, in respect of the production of BSA and BDO.  

“Third Party Acquirer” has the meaning set forth in Section 11.2.1. 

“Trademark License Agreement” has the meaning set forth in Section 16.4.1. 

“Trademarks” means all trademarks, service marks, trade names, service names, brand names, trade dress, together
with the goodwill associated with any of the foregoing, and all applications, ITU Applications, registrations and renewals thereof. 
 “Trade Secrets” means any trade secrets or similar forms of protection for confidential information, including invention disclosures, formulae, recipes, specifications (including
information regarding materials, ingredients, tools, apparatus, sources, vendors), procedures, processes, methods, techniques, ideas, creations, inventions and discoveries (whether patentable or unpatentable and whether or not reduced to practice),
improvements, know-how, research and development, technical data, designs, models, algorithms, subroutines and similar confidential information. 
 “Transfer” has the meaning set forth in Section 10.2.1. 
 “Transfer Negotiation Period” has the meaning set forth in Section 11.1.3. 
 “Transferring Shareholder” has the meaning set forth in Section 11.1.1. 
 “Transfer Terms” has the meaning set forth in Section 11.1.3. 
 “Tribunal” has the meaning set forth in Section 22.2.3. 
 “Valuation Deadline” has the meaning set forth in Section 5.3.2. 
 1.2. Interpretation. 
 1.2.1. The terms “herein,”
“hereof,” “hereto,” “hereinafter” and similar terms, as used in this Agreement, in each case shall refer to this Agreement as a whole and not to any particular section, paragraph, sentence or other subdivision of this
Agreement. Whenever the words “include,” “includes” or “including” are used, they shall be deemed to be followed by the words “without limitation” or “but not limited to” or words of like import. The
term “or,” as used herein, is not exclusive. Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other gender, masculine, feminine
or neuter, as the context indicates is appropriate. 
 1.2.2. Any reference to a statute or statutory provision shall be
construed as a reference to the same as it may have been, or may from time to time be, amended, modified or re-enacted and to any applicable rules or regulations promulgated thereunder. Any reference to any agreement or document (including this
Agreement) shall be construed as a reference to such agreement or document as amended, modified or supplemented and in effect from time to time and shall include a reference to any document which amends, modifies or supplements it, or is entered
into, made or given pursuant to or in accordance with its terms. 

  
 - 9 -

 tk-420278 
 *
Confidential treatment requested 

 1.2.3. Any reference to any Person in any capacity includes a reference to its permitted
successors and assigns in such capacity and, in the case of any Governmental Authority, any Person succeeding to its functions and capacities. 
 1.2.4. Each party has participated in the drafting of this Agreement, and any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the
construction or interpretation of this Agreement. 
 1.2.5. All references in this Agreement to “Section,”
“Exhibit”, “Schedule” or “Annex” (or similar references) shall be deemed to be references to a section of, or exhibit, schedule or annex to, this Agreement, unless the context otherwise requires. Headings set forth in
this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 1.2.6
Closing in Escrow; Deliveries; Release from Escrow. This Agreement, the Technology License Agreement, the Subscription Agreements and the documents listed or referred to under Sections 8(c), 8(d) and 8(e) of the respective Subscription
Agreements are referred to collectively herein as the “Closing Documents”. BioAmber Lux, Mitsui and the Company recognize that, subject to the delivery of the First Disbursement (as defined in this Section 1.2.6)
and to the escrow provisions of this Section 1.2.6, to their respective knowledge, the closing conditions set forth at Sections 8 and 9 of their respective Subscription Agreements are satisfied and, accordingly, the Initial Closing (as
defined in the Subscription Agreements) is completed and the Initial Closing Date (as defined in the Subscription Agreements) is November 2, 2011. The Closing Documents shall be held in escrow by Boivin Desbiens Senécal, g.p., as Company
counsel (the “Company Counsel”), and may not be released to any party, until the earlier of: (a)(i) the receipt by Company Counsel in trust (or directly by the Company, if so agreed by the relevant parties) of the first
disbursement of each applicable party’s initial capital contribution as set forth in Schedule 5.1 [***] (the “First Disbursement”), which each of BioAmber Lux and Mitsui agree to provide to Company Counsel (or
directly to the Company) at the latest on 5:00 p.m. New York City time on November 30, 2011, notwithstanding the fact that this Agreement and the Subscription Agreements are subject to escrow pursuant to the terms of this
Section 1.2.6, but provided that the event described in the succeeding clause (ii) has occurred and (ii) the execution and delivery by all parties thereto of the Government Finance Agreements listed under subsection B) of
Schedule 17.1.8 (the foregoing clauses (i) and (ii), collectively, the “Release Conditions”), and (b) 5:00 p.m. New York City time on November 30, 2011, unless another time or date is agreed to in
writing by BioAmber Lux and Mitsui and notified to Company Counsel (the “Escrow Release Time”). On the Escrow Release Time, subject to the satisfaction (or waiver by BioAmber Lux and Mitsui) of the Release Conditions, Company
Counsel shall release the Closing Documents in its possession from escrow to their intended recipients and remit the First Disbursement in its possession (if any) to the Company. In the event that, as of the Escrow Release Time, the Release
Conditions are not satisfied, Company Counsel shall so notify each of BioAmber Lux and Mitsui and request instructions in respect of the Closing Documents and the First Disbursement in its possession (if any). If so requested by either of such
parties, Company Counsel shall forthwith return to BioAmber Lux and Mitsui their respective share of the First Disbursement and the Closing Documents received from each of them (if any), it being understood that, in such event, this Agreement shall
thereafter be deemed null and void ab initio (except for any rights or obligations thereupon accrued under this Section 1.2.6). 

  
 - 10 -

 tk-420278 
 *
Confidential treatment requested 

	2.	THE COMPANY 

 2.1.
Formation. The BioAmber Parties have formed the Company as a Canadian corporation in accordance with Applicable Law and subject to the terms and conditions set forth in this Agreement. 

2.2. Name. The name of the Company shall be Bluewater Biochemicals Inc. unless changed by mutual agreement of the Shareholders. It
is the intent of the Shareholders to change the name of the Company to “BioAmber Sarnia Inc.” prior to commencing operations at the Initial Plant. All business of the Company shall be conducted in the name of the Company. 

2.3. Principal Place of Business. The Company’s principal place of business shall be 1265 Vidal Street South, Sarnia, Ontario
N7T 7M2 unless changed to a different location by mutual agreement of the Shareholders (it being understood that the foregoing address may change once the Initial Plant is built, as such address is the current address of the landlord of the site on
which the Initial Plant will be built). 
 2.4. Subsidiaries; Shareholders. The Company shall have no subsidiaries except
if and to the extent agreed by all of the Shareholders. The Company shall have no Shareholders (other than the then-current Shareholders) except as expressly permitted by this Agreement or as all of the Shareholders may otherwise agree. 

2.5. Foreign Qualification. Prior to the Company conducting business in any jurisdiction in which it is required, as a result of
such activities, to qualify to do business, the Company shall comply with all requirements necessary to qualify it to do business in such jurisdiction. Each Shareholder shall execute and deliver any certificates and other instruments that are
necessary or appropriate for the Company to qualify and continue to do business as a foreign entity in such jurisdiction. 

2.6. Term. The Company shall continue in existence from its date of formation until its dissolution in accordance with the
provisions of this Agreement, its Charter Documents and Applicable Law. 
  

	3.	BUSINESS OF THE COMPANY 

3.1. Business. The business of the Company (the “Business”) shall be to finance, build and operate a plant
in Sarnia, Ontario, Canada to produce and sell BSA and BDO using the BioAmber Technology, and having the capacity (including expanded capacity) contemplated by Section 3.2 (the “Initial Plant”). 

3.2. Initial Plant Commission and Capacity. As of the date hereof, the Shareholders’ present expectation is that the Initial
Plant will be commissioned by [***] with an initial annual capacity of approximately 17,000 MT of BSA, and that the Initial Plant will be expanded in [***] to eventually produce a total of 34,000 MT of BSA and, subject to confirmation of feasibility
of the relevant technology, 23,000 MT of BDO annually. 

  
 - 11 -

 tk-420278 
 *
Confidential treatment requested 

 3.3. Initial Plant Construction Budget and Schedule. The budget and schedule for the
construction of the Initial Plant is attached hereto as Schedule 3.3 (the “Construction Budget and Schedule”). 
  

	4.	ADDITIONAL PLANTS 

 4.1.
Additional Plants. In addition to the Initial Plant, the BioAmber Parties and Mitsui intend to build and operate two (2) additional plants to produce and sell BSA and BDO using the BioAmber Technology (collectively, the
“Additional Plants”), as follows: 
 4.1.1. Thailand Additional Plant. The first of the
Additional Plants to be located in Thailand, with a target annual capacity of 65,000 MT of BSA and 50,000 MT of BDO, or a combination thereof as the applicable parties may agree. The BioAmber Parties and Mitsui may consider the possibility of
building this Additional Plant in cooperation with PTT-MCC Biochem, if mutually acceptable terms therefor can be agreed, including PTT-MCC Biochem securing an agreed portion of the off-take of BSA and possibly BDO produced by such Additional Plant.

 4.1.2. U.S.A./Brazil Additional Plant. The second of the Additional Plants, with a target annual capacity of 65,000 MT
of BSA and 50,000 MT of BDO, or some combination thereof as the applicable parties may agree, to be located in either: (a) [***], U.S.A., [***]; or (b) Brazil, [***]. 

4.2. Construction of Additional Plants. The BioAmber Parties and Mitsui shall discuss in good faith the construction and operation
of the Additional Plants, according to terms and conditions between them similar to those applicable to the Initial Plant or as such parties may otherwise agree. The BioAmber Parties and Mitsui will [***]. 

4.3. PBS Technology. If the BioAmber Parties and Mitsui agree to jointly develop either or both of the Additional Plants, [***]

 4.4. Non-Binding Provisions. Notwithstanding anything herein to the contrary, the provisions of each of Sections
4.1, 4.2 and 4.3 are a statement of intent only and are not, and shall not be deemed to be, binding obligations of either of the BioAmber Parties or Mitsui. Without limiting the generality of the foregoing, as between such parties,
none of the BioAmber Parties nor Mitsui shall have any obligation in respect of the construction of any of the Additional Plants, which construction is subject to, among other things, satisfactory market feasibility studies, agreement on capital
budgets and obtaining necessary internal approvals, all at the sole discretion of each such party. 
 4.5. Exclusivity.
For a period of [***] years from the date hereof (which period may be extended upon mutual agreement by BioAmber and Mitsui), none of the BioAmber Parties nor Mitsui shall, and each such party shall cause its Affiliates not to, without the prior
written consent of BioAmber (in the case of Mitsui) or Mitsui (in the case of the BioAmber Parties), [***]. Notwithstanding the preceding sentence, [***]. For purposes of the preceding sentence, [***]. 

  
 - 12 -

 tk-420278 
 *
Confidential treatment requesteds 

	5.	FINANCING OF THE COMPANY 

5.1. Financing Commitments of the Shareholders. 
 5.1.1. BioAmber Lux Initial Capital Contribution. BioAmber Lux shall provide to the Company an aggregate initial capital contribution of [***] (or any lesser amount as may be determined by the
Board pursuant to clause (ii) below), in consideration of the issuance of BioAmber Lux’s Shares set forth opposite its name in Schedule 5.1, to be disbursed as follows: (i) as provided in its Share Subscription Agreement,
[***], and (ii) within seven (7) days following any resolution by the Board to such effect communicated in writing to the Shareholders, one or more additional disbursements not to exceed [***] in the aggregate; provided, that in
order to make any capital call pursuant to the foregoing clause (ii), the Board shall make a simultaneous capital call from Mitsui pursuant to Section 5.1.2(ii) in such amount that would allow Mitsui to preserve its Pro Rata Share after
giving effect to the capital call made from BioAmber Lux. 
 5.1.2. Mitsui Initial Capital Contribution. Mitsui shall
provide to the Company an aggregate initial capital contribution of [***] (or any lesser amount as may be determined by the Board pursuant to clause (ii) below), in consideration of the issuance of Mitsui’s Shares set forth opposite its
name in Schedule 5.1, to be disbursed as follows: (i) as provided in its Share Subscription Agreement,, [***], and (ii) within seven (7) days following any resolution by the Board to such effect communicated in writing to the
Shareholders, one or more additional disbursements not to exceed [***] in the aggregate; provided, that in order to make any capital call pursuant to the foregoing clause (ii), the Board shall make a simultaneous capital call from BioAmber
Lux pursuant to Section 5.1.1(ii) in such amount that would allow BioAmber Lux to preserve its Pro Rata Share after giving effect to the capital call made from Mitsui. 

5.1.3. Additional Shareholder Capital Contributions. If requested by the Board pursuant to a capital call in writing made to all,
but not less than all, of the Shareholders as a result of the aggregate amounts payable in respect of the EPC Contract exceeding [***], each of BioAmber Lux and Mitsui shall provide to the Company an additional capital contribution equal to up to
[***] and [***], respectively, in each case within thirty (30) days of the date of such capital call (or such longer period as the Board may determine, which period shall apply equally to all Shareholders), it being understood that, subject to
the foregoing respective maximum amounts, any such additional capital contribution requested by the Board shall be allocated between the Shareholders in accordance with their respective Pro Rata Shares. 

5.1.4. Loan Guarantees. Subject to Section 5.4, if requested by the Board pursuant to a written request made to all,
but not less than all, of the Shareholders, each of BioAmber Lux and Mitsui shall provide guarantees in favor of Lenders in respect of loans provided by such Lenders to the Company up to an aggregate amount equal to [***] and [***], respectively, in
each case within thirty (30) days of the date of such request (or such longer period as the Board may determine, which period shall apply equally to all Shareholders), it being understood that, subject to the foregoing respective maximum
amounts, (i) any such guarantees requested by the Board shall be allocated between the Shareholders in accordance with their respective Pro Rata Shares and (ii) if and to the extent that any such Lender so requests, such guarantees shall
be provided by BioAmber on behalf of BioAmber Lux, which guarantees so provided by BioAmber shall be deemed to have been allocated to BioAmber Lux’s Pro Rata Share. In the event that Mitsui and BioAmber Lux

  
 - 13 -

 tk-420278 
 *
Confidential treatment requested 

 
(and/or BioAmber) provide guarantees in favor of Lenders according to the terms of this Section 5.1.4, the Company shall pay to each of Mitsui and BioAmber Lux (and/or BioAmber) an annual
fee in respect of their respective guarantees of the loans provided by such Lenders in the amounts and pursuant to such terms as Mitsui and BioAmber mutually agree. 
 5.1.5 . Mitsui Maximum Commitment. For the avoidance of doubt, notwithstanding anything herein to the contrary, in no event shall Mitsui be obligated to provide capital contributions, guarantees or
other financial support to or on behalf of the Company pursuant to this Section 5.1, Section 5.2 or otherwise if and to the extent that the amount of such capital contributions or exposure under such guarantees or other
financial support, together with all amounts previously financed by (and not repaid to) Mitsui and all amounts for which Mitsui is then currently exposed with respect to guarantees or other financial support, exceed [***] (the “Mitsui
Maximum Commitment”). For further clarity, however, Mitsui shall have the right, in its sole discretion, to provide up to its Pro Rata Share of any financial support requested by the Board in excess of the Mitsui Maximum Commitment.

 5.2. Additional Financial Contributions. 
 5.2.1. Additional Contributions. If the Board determines that the Company requires financial contributions in excess of the commitments set forth in Section 5.1, in the form of equity,
loans, guarantees or otherwise (any such financial contribution, an “Additional Contribution”), it shall provide written notice thereof to each Shareholder, setting forth the nature, amount and other relevant terms of the
Additional Contribution (a “Contribution Notice”). The Shareholders shall thereupon engage in good faith discussions in respect of such Additional Contribution, including the terms and intended purpose thereof, for a period
of fifteen (15) days (or such other period as the Shareholders may mutually agree) after the date the Board delivered to the Shareholders the relevant Contribution Notice, and the Board shall implement any agreement in respect of such
Additional Contribution that the Shareholders may thereby reach. Subject to the preceding sentence, each Shareholder shall have the right, but not the obligation, to contribute up to its Pro Rata Share of any Additional Contribution, within thirty
(30) days after the expiration of the fifteen (15) day period (or such other period as the Shareholders may mutually agree) referred to in the preceding sentence (subject to such additional period of time as may be necessary to determine
the applicable per Share price in accordance with Section 5.3.2, if applicable). 
 5.2.2. Shortfall. In the
event that (i) the Board issues a Contribution Notice for an Additional Contribution in the form of equity, (ii) either Shareholder contributes less than its full Pro Rata Share of such Additional Contribution within the applicable period
therefor and (iii) the other Shareholder contributes its full Pro Rata Share of such Additional Contribution within the applicable period therefor, then such contributing Shareholder shall have the right, but not the obligation, to provide
funds to the Company up to the amount not contributed by the other Shareholder. In such event, the Company shall issue additional Shares to the contributing Shareholder, and the respective Pro Rata Shares of the Shareholders shall be adjusted, in
accordance with Section 5.3. For the avoidance of doubt, any reduction in Mitsui’s Pro Rata Share pursuant to this Section 5.2.2 shall proportionally reduce Mitsui’s economic right to receive dividends or other
distributions from the Company but shall not reduce or otherwise affect in any manner whatsoever any other rights of Mitsui hereunder, including its rights under Section 8. 

  
 - 14 -

 tk-420278 
 *
Confidential treatment requested 

 5.3 . Share Valuation. 

5.3.1 . Valuation Pre-Operational Date. For any capital call made by the Board to be funded prior to the Operational Date, the
price per Share to be issued pursuant to such capital call shall be equal to the per Share purchase price for the Shares acquired by Mitsui and BioAmber Lux pursuant to the Subscription Agreements, which price is equal to $10 per Share. 

5.3.2 . Valuation Post-Operational Date. Except as otherwise set forth in the Subscription Agreements for any Shares issued
thereunder on or after such date, for any capital call made by the Board to be funded on or after the Operational Date, the Shareholders shall discuss and negotiate in good faith on a valuation of the Company (as of the date of the applicable
capital call notice) for the purpose of determining the price per Share to be issued in the applicable capital call (each, a “Company Valuation”), and such price per Share shall be equal to the quotient of such Company
Valuation and the total number of then-issued and outstanding Shares (the “Financing Share Price”). If the Shareholders are unable to agree on the Company Valuation within thirty (30) days, or such other period as agreed
by the Shareholders, after receipt of the applicable capital call notice (the “Valuation Deadline”), then the Financing Share Price shall be equal to the Fair Market Value of the Shares as of the date of such capital call
notice and shall be determined by an appraisal as follows: 
 (a) the Shareholders shall discuss in good faith
with a view to agreeing on the appointment of an independent investment bank or independent accounting firm of recognized international standing (the “Appraiser”), and if the Shareholders reach agreement on the appointment of
the Appraiser within thirty (30) days after the Valuation Deadline, such Company Valuation shall be determined by the Appraiser in accordance with clauses (b) and (c) immediately below. If the Shareholders are unable to reach
agreement on and appoint the Appraiser within thirty (30) days after the Valuation Deadline, then the Appraiser shall be appointed by the International Centre for Expertise in accordance with the provisions for the appointment of experts under
the Rules for Expertise of the ICC. The cost, fees and expenses incurred in connection with the appointment of the Appraiser shall be borne equally between the Shareholders. 

(b) The parties agree that the basis for determining the Fair Market Value shall be the price that would be paid in an
arm’s-length sale between an informed and willing seller under no compulsion to sell and an informed and willing buyer under no compulsion to buy. 
 (c) The Appraiser shall submit its appraisal report to each of the Shareholders and the Company within thirty (30) days after the date of its appointment. The appraisal set forth in such appraisal
report shall be the definitive Fair Market Value of the Shares, and it shall be final and binding on the Shareholders for the purposes of this Section 5.3.2. 
 5.4 . Guarantees. Any obligations of the Shareholders (or BioAmber, as the case may be) in respect of third parties (whether arising from loan guarantees pursuant to Section 5.1.4 or
otherwise) shall be on a several or individual basis and not on a joint or collective basis, and no Shareholder shall be liable to third parties in respect of any obligation of any other Shareholder (or BioAmber, as the case may be). 

  
 - 15 -

 tk-420278 
 *
Confidential treatment requested 

	6.	NON-FINANCIAL CONTRIBUTIONS 

 6.1 . BioAmber Non-Financial Contributions. BioAmber shall make available to the Company the following functions and capabilities: [***]. 

6.2 . Mitsui Non-Financial Contributions. Mitsui shall make available to the Company the following functions and capabilities:
[***]. 
 6.3 . Provision of Non-Financial Contributions. The functions and capabilities referred to in Sections
6.1 and 6.2 shall be provided by each of BioAmber and Mitsui to the Company (a) by appointing appropriate Directors at no cost to the Company (other than as set forth in Section 8.2.12); (b) by seconding to the
Company personnel of such party, on terms, including costs to be charged to the Company, to be agreed (subject to Section 8.1.3); or (c) as BioAmber, Mitsui and the Company may otherwise agree. 

 

	7.	REDUCTION/TERMINATION OF CONTRIBUTIONS 

 7.1 . Reduction/Termination of Contributions. In the event of a reduction of any Shareholder’s Pro Rata Share, the obligation of such Shareholder (or BioAmber, as contemplated by
Section 5.1.4) to provide (a) loan guarantees pursuant to Section 5.1.4 or (b) any other form of financial support (including loans) to the Company shall be proportionally reduced or terminated, as applicable, to
the extent of any such reduction (it being understood that BioAmber’s obligation to provide any financial support to the Company shall be so reduced or terminated to the extent of any reduction in BioAmber Lux’s Pro Rata Share).

 7.2 . Termination of Secondments/Assignments. In the event that a Shareholder shall hold no Equity Securities of the
Company, any personnel then seconded or otherwise assigned to the Company by such Shareholder shall be released from such secondment or assignment, simultaneously with, or as promptly as practicable after, the date on which such Shareholder ceases
to hold any such Equity Securities. 
 7.3 . Action by the Parties. If and to the extent required pursuant to such
Sections, the parties shall take all action necessary to effect the reduction/termination of financial support obligations and the release of seconded/assigned personnel contemplated by Sections 7.1 and 7.2 (including by providing replacement
guarantees or otherwise). In furtherance, and without limiting the generality, of the foregoing, the parties also agree that if Mitsui shall hold no Equity Securities of the Company, then BioAmber Lux hereby undertakes to deploy its best efforts in
order to obtain from the concerned Lenders a complete release for any guarantee granted by Mitsui in connection with any loan provided by such Lenders to the Company. 

  
 - 16 -

 tk-420278 
 *
Confidential treatment requested 

	8.	MANAGEMENT OF THE COMPANY 

8.1 . Shareholders. 
 8.1.1 . Voting. Each Shareholder shall vote its Shares at all ordinary or extraordinary meetings of Shareholders, and shall take all other actions necessary, to give effect to the provisions of
this Agreement. Except as otherwise provided for herein or by Applicable Law, the adoption of any resolution at a Shareholders’ meeting shall require the affirmative vote of a simple majority of the then-issued and outstanding voting Shares.

 8.1.2 . Actions Requiring Unanimous Shareholder Consent [***]. Subject to Section 18.1.2, the following
actions are subject to, and the Company shall not take any such action without first obtaining, the prior written consent of each Shareholder: 
 [***] 
 provided, that if the Shareholders are unable to agree on any such action within
thirty (30) days after the Board submits, in writing, such action for approval of the Shareholders (which submission shall set forth, in reasonable detail, a description of the proposed action, the purpose and other relevant terms thereof),
such proposed action shall be submitted by the Shareholders for further discussion to their respective designated senior representatives, who shall have authority to reach an agreement on behalf of the applicable Shareholder. If such designated
senior representatives remain unable to reach an agreement within thirty (30) days after the date on which the proposed action was submitted to them, [***]. 
 8.1.3 . Actions Requiring Unanimous Shareholder Consent. Subject to Section 18.1.2, the following actions are subject to, and the Company shall not take any such action without, the
prior written consent of each Shareholder: 
 (a) any change in any service or royalty fee paid by the Company to
BioAmber or any Affiliate thereof; 
 (b) subject to Section 19, the dissolution, liquidation or
winding up of the Company (or any action for such purpose); 
 (c) the sale or purchase by the Company of any
asset for an amount in excess of [***] or that is otherwise material to the Company (other than raw materials purchased, or inventory sold, in the ordinary course of business of the Company or as otherwise contemplated in an approved business plan
or annual budget of the Company); 
 (d) any change in the scope of the Business; 

(e) any change in the accounting principles or practices of the Company; 

(f) any transaction between the Company and any Shareholder or Affiliate thereof other than (i) the issuance of
Shares to the Shareholders pursuant to the terms of the Subscription Agreements or this Agreement, as applicable, and (ii) the transactions contemplated by the Ancillary Agreements in accordance with the respective terms and conditions thereof;

  
 - 17 -

 tk-420278 
 *
Confidential treatment requested 

 (g) any borrowing or other incurrence of indebtedness of any kind, or the
granting of any security or guarantees (unless contemplated by an approved business plan or annual budget of the Company); 
 (h) the making of loans or provision of guarantees or other financial support by the Company in favor of third parties; 

(i) commencing, or making any significant decision relating to, any Proceeding outside the ordinary course of business of
the Company; 
 (j) any change to the Company’s Charter Documents; 

(k) any reorganization, amalgamation, merger or similar transaction by or involving the Company; 

(l) the closure of, or cessation of activities at, the Initial Plant (other than temporary stoppages in the ordinary
course of business of the Company); and 
 (m) any expenses of whatever nature incurred by the Company, until the
time that all Governmental Approvals set forth in Schedule 17.1.7 that are necessary or required in connection with the ownership and use by the Company of its properties and assets and the operation of the Business are obtained. 

8.1.4 . Meetings. The Board shall convene ordinary meetings of the Shareholders as required by Applicable Law and as set forth in
the Company’s Charter Documents, and shall convene an extraordinary meeting of the Shareholders when requested by any Director (other than a Director nominated by a Defaulting Shareholder). All Shareholders’ meetings shall be conducted in
accordance with the terms of this Agreement and the Company’s Charter Documents, and shall be presided over by the Chairman or, in his or her absence, any other Director elected to preside over the meeting by the then-attending Directors. The
Board shall prepare the agenda for each Shareholders’ meeting and may provide a recommendation with respect to any business set forth on such agenda. The language for all Shareholders’ meetings shall be English, and all minutes and other
documents presented to Shareholders shall be prepared in English. 
 8.1.5 . Notice. The Secretary shall give notice to
the Shareholders (other than any Defaulting Shareholder) specifying the date and time for each Shareholders’ meeting, accompanied by an agenda specifying the business of such meeting; provided, that in the event the Secretary fails to
timely provide such notice, the Director calling such meeting may provide such notice himself or herself. Not fewer than fourteen (14) days’ prior written notice from the Secretary shall be given to all Shareholders (other than any
Defaulting Shareholder); provided, however, that such notice period may be reduced with the written consent of all Shareholders entitled to vote at such meeting. 
 8.1.6 . Quorum. Subject to Section 18.1.2, at any Shareholders’ meeting, presence of Shareholders holding at least seventy five percent (75%) of the then-issued and
outstanding voting Shares shall constitute a quorum, subject to the following provisions of this Section 8.1.6. If such a quorum is not present within one (1) hour from the time appointed for the Shareholders’ meeting due to
the absence of the duly authorized representative(s) of a Shareholder (the “Absent 

  
 - 18 -

 tk-420278 
 *
Confidential treatment requested 

 
Shareholder”), the meeting shall be postponed to such place and time as the Chairman shall decide, which shall be no earlier than fourteen (14) days after written notice
of such postponed meeting has been given to all Shareholders. If, at such postponed meeting, such quorum is still not present due to the continuing absence of the Absent Shareholder, the Shareholders present at such postponed meeting shall be deemed
a quorum and may transact the business for which the postponed meeting was originally convened (except with respect to any action that may only be approved in accordance with Section 8.1.2 or 8.1.3). 

8.1.7 . Shareholders’ Access. Each Shareholder (through its designated representatives) other than a Defaulting Shareholder,
which shall not have such right, shall be entitled to examine the Books and Records of the Company and shall have reasonable access, at all reasonable times and with prior written notice, to any and all properties and assets of the Company (subject
to standard security measures applicable at any such property). 
 8.1.8 . No Authority of Shareholders to Act on Behalf of
Company. No Shareholder shall act as an agent of the Company or have any authority to act for or to bind the Company. 
 8.2
.. Board. 
 8.2.1 . Authority of the Board. Subject to the provisions of this Agreement (including Sections
8.1.2 and 8.1.3), the Company’s Charter Documents and Applicable Law, the management of the Company shall be exercised by the Board, which shall have full power and discretion to take all actions that it considers necessary or
desirable in connection with the management of the Company. 
 8.2.2 . Number and Composition. The Board shall initially
consist of five (5) Directors. BioAmber Lux shall have the right to nominate three (3) Directors and Mitsui shall have the right to nominate two (2) Directors. Each Shareholder shall vote its Shares for the appointment of any
Director(s) nominated by the other Shareholder. 
 8.2.3 . Chairman. The Chairman shall be selected by a majority vote of
the Directors then in office. 
 8.2.4 . Removal and Replacement of Directors. A Director shall be removed from the
Board, with or without cause, only upon the affirmative vote of the Shareholders in accordance with this Section 8.2.4. Each Shareholder shall vote its Shares for the removal of a Director upon the written request of the Shareholder that
nominated such Director. Otherwise, no Shareholder shall vote for the removal of any Director. In the event that any Director resigns or is removed in accordance with this Section 8.2.4, the Shareholder that nominated such Director shall
have the right to nominate such Director’s successor or replacement, and such successor or replacement Director shall be nominated and elected on or as soon as practicable after the date of such resignation or removal. 

8.2.5 . Directors’ Access. Each Director (other than a Director nominated by a Defaulting Shareholder, who shall not have
such right) shall be entitled to examine the Books and Records of the Company and shall have reasonable access, at all reasonable times and with prior written notice, to any and all properties and assets of the Company (subject to standard security
measures applicable at any such property). 

  
 - 19 -

 tk-420278 
 *
Confidential treatment requested 

 8.2.6 . Frequency and Location of Board Meetings; Deliberations. Meetings of the
Board shall take place at least once each calendar quarter. Meetings shall be held in a location approved by all of the Directors or, failing such approval, at the principal place of business of the Company. All deliberations at Board meetings shall
be held, and all resolutions shall be passed, in English. 
 8.2.7 . Notice. A Board meeting may be called by any
Director (other than any Director nominated by a Defaulting Shareholder), by written notice to the Secretary specifying the date, time and agenda for such meeting. The Secretary shall, upon receipt of any such notice, provide a copy of such notice
to all Directors (other than any Director(s) nominated by a Defaulting Shareholder), accompanied by an agenda specifying the business of such meeting and copies of all documents and other information materially relevant for such meeting;
provided, that in the event the Secretary fails to timely provide such notice, the Director calling such meeting may provide such notice himself or herself. Not less than fourteen (14) days’ prior notice, delivered in writing, shall
be given to all Directors (other than any Director(s) nominated by a Defaulting Shareholder); provided, however, that such notice period (i) shall not apply in the case of an adjourned meeting pursuant to Section 8.2.8 and
(ii) may be reduced with the written consent of all of the Directors entitled to vote at such meeting. 
 8.2.8 .
Quorum. Subject to Section 18.1.2, attendance of at least one (1) Director nominated by BioAmber Lux and one (1) Director nominated by Mitsui shall be required to constitute a quorum for any meeting of the Board, subject
to the following provisions of this Section 8.2.8. If such a quorum is not present within one (1) hour from the time specified for any duly called meeting, the meeting shall be postponed to such place and time as a majority of the
then-attending Directors shall decide or, in the absence of such decision, as the Chairman shall decide, which shall be no earlier than seven (7) days after written notice of such postponed meeting has been given to all Directors, and, at any
such postponed meeting, a quorum shall consist of, at least, a majority of the Directors. 
 8.2.9 . Voting. Subject to
Section 18.1.2, at any Board meeting, each Director may exercise one (1) vote, and the adoption of any resolution of the Board shall require the affirmative vote of a simple majority of the Directors present at a duly constituted
meeting of the Board. 
 8.2.10 . Means of Participation. To the extent permitted by Applicable Law, (i) Directors
may participate in a Board meeting by telephone or video conference, provided that each Director can hear and be heard by all other Directors throughout the meeting, and (ii) participation by such means shall constitute presence for
purposes of the quorum provisions of Section 8.2.8. 
 8.2.11 . Action by Written Consent. To the extent
permitted by Applicable Law, any action that may be taken by the Directors at a duly constituted meeting may be taken by a written resolution (in one or more counterparts) signed by all the Directors entitled to vote at such meeting. 

8.2.12 . No Compensation; Expenses. The Directors shall not receive any compensation from the Company for their service as
Directors. The Company shall reimburse the Directors for their reasonable out-of-pocket expenses in connection with serving as Directors, including any travel, lodging and other costs of attendance at meetings of the Board. 

  
 - 20 -

 tk-420278 
 *
Confidential treatment requested 

 8.2.13 . Indemnification of Directors; Director Insurance. The Company shall
indemnify and hold harmless each of the Directors, in accordance with the terms and subject to the conditions set forth in an indemnification agreement, which the Company and the Shareholders shall negotiate in good faith to execute as promptly as
practicable after the date hereof (the “Indemnification Agreement”). As soon as practicable after the date hereof, the Company shall purchase, and maintain at all times, Director insurance (with the amount of the coverage
determined by the Board) for all Directors, retroactive to the date of formation of the Company and payable to the Company as beneficiary. 
 8.3 . Officers. The Company shall have such officers as the Board may appoint from time to time, and all such officers shall be subject to removal at any time at the discretion of the Board. Such
officers shall have such duties as may be delegated thereto by the Board and as are customarily possessed by officers in similar positions in the relevant jurisdiction (except as such duties may be restricted by the Board), subject to the provisions
of this Agreement, the Company’s Charter Documents and Applicable Law. 
 8.4 . Plant Manager. The day-to-day
operations of the Initial Plant shall be responsibility of the Plant Manager, who, subject to Section 8.1.2, shall be nominated by BioAmber Lux. The Plant Manager shall report directly to the Board. 

8.5 . Secondment. Mitsui shall have the right, but not the obligation, to second and appoint a representative to the Company, and
to remove any such appointed representative, in Mitsui’s discretion. Any such secondment shall be on such terms, including as to cost to be charged to the Company, to be agreed among Mitsui, BioAmber and the Company (subject to
Section 8.1.3). 
  

	9.	OTHER OPERATIONAL MATTERS 

9.1 . Dividend/Distribution Policy. At least once every Financial Year, all funds of the Company then available for distribution
under Applicable Law, after deducting only any amounts that are required to (i) meet then-legally binding commitments and reasonably foreseeable contingencies and (ii) maintain or expand the Initial Plant in accordance with the
then-approved annual budget, shall be distributed to the Shareholders as dividends in accordance with their respective Pro Rata Shares or in any other matter unanimously agreed by the Shareholders. 

9.2 . Books and Records; Financial Statements. 
 9.2.1 . Books and Records. The Company shall keep and maintain Financial Statements, books, records and other accounts, in reasonable detail (collectively, the “Books and
Records”), which accurately and fairly reflect its transactions and dispositions of assets, governance and other operational matters. The Company shall further keep and maintain the Books and Records at all times in compliance with all
record keeping and reporting requirements required by Applicable Law. 
 9.2.2 . Financial Statements. The Financial
Statements shall be maintained in Dollars and in accordance with IFRS and shall be audited annually by Deloitte & Touche or such other of the “Big Four” international accounting firms as is selected by the Board. The Company shall
devise and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed and access to assets is permitted only in accordance

  
 - 21 -

 tk-420278 
 *
Confidential treatment requested 

 
with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of periodic financial statements and to maintain accountability
for assets; and (iii) actual assets and recorded assets (and related accounting values) are compared at reasonable intervals and appropriate action is taken to address any inconsistencies. 

9.3 . Information Rights. 
 9.3.1 . Financial Statements. The Company shall provide to each Shareholder (i) within ninety (90) days after the end of each Financial Year, the annual audited Financial Statements for
such Financial Year; (ii) within thirty (30) days after the end of each quarter of each Financial Year, quarterly unaudited Financial Statements for such quarter; and (iii) within ten (10) days after the end of each month of each
Financial Year, monthly trial balances of the Company. 
 9.3.2 . Construction Reports. During the period prior to the
Operational Date, the Company shall provide to each Shareholder monthly written reports setting forth in reasonable detail the progress of the construction of the Initial Plant, including (i) any material difficulties or delays encountered and
all measures being taken (or considered) to address such difficulties or delays and (ii) the costs associated with the construction to date and how such costs compare to those set forth in the Construction Budget and Schedule. 

9.3.3 . Other Information. The Company shall prepare and provide, at its expense, any additional information or materials that may
be reasonably requested by any Shareholder to enable it to comply with its internal policies regarding accounting and disclosure requirements as well as the requirements of any applicable securities regulatory authority, including any stock exchange
on which the securities of such Shareholder (or any Affiliate thereof) are traded. 
 9.4 . Insurance. The Company shall
obtain and maintain, at its cost, adequate insurance in respect of its assets, properties and operations as determined by the Board, and the other parties shall reasonably cooperate, if and to the extent requested by the Company, to assist the
Company in obtaining such insurance. 
  

	10.	ENCUMBRANCE OR TRANSFER OF SHARES 

 10.1 . Proxies and Voting Trusts. Each of the BioAmber Parties and Mitsui agrees not to grant to any third party any proxy or enter into, or become bound by, any voting trust with respect to its
Shares, or enter into arrangements of any kind with any Person with respect to its Shares, in any such case in a manner that is inconsistent with this Agreement. 
 10.2 . Restrictions on Transfer. 
 10.2.1 . No Transfers or
Encumbrances. Except with the prior written consent of the other Shareholder or as otherwise expressly permitted by this Agreement, no Shareholder shall, directly or indirectly, (i) sell, assign, donate or otherwise transfer or dispose of,
in any way or manner whatsoever, whether voluntarily or involuntarily, by operation of law or otherwise (collectively, “Transfer”), or (ii) pledge, mortgage, hypothecate or otherwise encumber, in any way or manner
whatsoever, whether voluntarily or involuntarily, by operation of law or otherwise (collectively, as the context may require, “Encumber” or “Encumbrance”), the legal or beneficial ownership of, or
economic benefits pertaining to, any of its Shares. Each certificate for any Shares now held or hereafter acquired by any Shareholder shall, for as long as this Agreement is effective, bear an appropriate legend regarding the Transfer restrictions
applicable in respect of such Shares. 

  
 - 22 -

 tk-420278 
 *
Confidential treatment requested 

 10.2.2 . Invalid Transfers/Encumbrances. Any purported Transfer or Encumbrance of
Shares in violation of this Agreement shall be null and void and shall not operate to Transfer or Encumber any right, title or interest to or in favor of the purported transferee, and the Company shall not recognize or give effect to any such
purported Transfer or Encumbrance. 
 10.2.3 . Permitted Transfers. Notwithstanding anything to the contrary contained
herein, each Shareholder may Transfer all or a portion of its Shares to a direct or indirect majority owned subsidiary of such Shareholder (or, in the case of BioAmber Lux, to BioAmber or another direct or indirect majority owned subsidiary of
BioAmber) (each, a “Permitted Transferee”); provided, that (a) such Shareholder shall pay all costs, including any taxes and fees, associated with such Transfer, and (b) as conditions precedent to the
effectiveness of such Transfer, (i) any Permitted Transferee to whom Shares are transferred shall agree to be bound by the terms of this Agreement by entering into a Joinder Agreement with the Company, (ii) BioAmber or Mitsui, as
applicable, shall guarantee all obligations of such Permitted Transferee under this Agreement pursuant to a guarantee agreement in form and substance reasonably acceptable to BioAmber or Mitsui, as applicable, (iii) any Consents required in
connection with such Transfer shall have been obtained, (iv) such Shareholder shall cause such Permitted Transferee to re-transfer all transferred Shares to such Shareholder (or another Permitted Transferee thereof) in accordance with the terms
hereof prior to it ceasing to be a direct or indirect majority owned subsidiary of such Shareholder (or, in the case of BioAmber Lux, of BioAmber) and (v) notwithstanding such Transfer, the transferring Shareholder shall remain solely
responsible under the Ancillary Agreements to which it is a party. Any Permitted Transferee to whom Shares are transferred in accordance with this Agreement shall be entitled to the rights and benefits of the transferring Shareholder under this
Agreement as if it where an original party hereto, and any reference herein to a particular Shareholder shall be deemed to be a reference to such Shareholder and its Permitted Transferees. 

 

	11.	RIGHT OF FIRST OFFER; DRAG-ALONG; CO-SALE 

 11.1 . Right of First Offer. 
 11.1.1 . Right of First Offer. A
Shareholder (a “Transferring Shareholder”) may propose to Transfer all (but not less than all) of its Shares (the “Offered Shares”) to any Person who is not a Permitted Transferee; provided,
that the other Shareholder (the “Offering Shareholder”) shall have a right of first offer in respect of the Offered Shares in accordance with the provisions of this Section 11.1. 

11.1.2 . Offer Notice. The Transferring Shareholder shall give prior written notice (the “Offer Notice”)
to the Offering Shareholder of the Transferring Shareholder’s desire to Transfer the Offered Shares to a Person who is not a Permitted Transferee. 
 11.1.3 . Transfer Negotiation Period; Closing. If within [***] days after the date on which it received the Offer Notice, the Offering Shareholder provides to the Transferring Shareholder written
notice of its interest in purchasing the Offered Shares (a “ROFO Exercise Notice”), for a period of [***] days after the date on which the Offering Shareholder received the

  
 - 23 -

 tk-420278 
 *
Confidential treatment requested 

 
Offer Notice (the “Transfer Negotiation Period”), the Transferring Shareholder and the Offering Shareholder shall negotiate in good faith with the objective of mutually
agreeing on the price and other terms and conditions for the Offering Shareholder’s purchase of the Offered Shares (collectively, the “Transfer Terms”). During the Transfer Negotiation Period, the Transferring
Shareholder shall not solicit any offer from, discuss, engage in negotiations or enter into any Contract with, any Person (other than the Offering Shareholder) with respect to the Offered Shares. If the Transferring Shareholder and the Offering
Shareholder reach an agreement on the Transfer Terms, the closing of such Transfer shall occur, subject to obtaining any required Consents, within [***] days after the date of such agreement. 

11.1.4 . Transfer to Third Parties. If (x) the Offering Shareholder fails to provide a ROFO Exercise Notice within the period
therefor set forth in Section 11.1.3 or (y) the Transferring Shareholder and the Offering Shareholder are unable to reach an agreement on the Transfer Terms within the Transfer Negotiation Period, the Transferring Shareholder shall
be entitled, subject to, if the Offering Shareholder is Mitsui (or its Permitted Transferee), Section 11.3, to offer and Transfer the Offered Shares, within a period of [***] days after the expiration of the Transfer Negotiation Period,
to any other Person for a price and on other terms no more favorable to such Person than the price and other terms last proposed by the Transferring Shareholder to the Offering Shareholder during their negotiation as contemplated by
Section 11.1.3 (or, absent such proposal, the price and other terms last proposed by the Offering Shareholder to the Transferring Shareholder during such negotiation) (the “Offering Shareholder Terms”), except in
the event referred to in clause (x) above of this Section 11.1.4, in which case the Transferring Shareholder may so offer and Transfer the Shares to such Person at any price and on any other terms as the Transferring Shareholder and
such Person may agree. If such Transfer is not consummated within such [***] day period, the Transferring Shareholder shall be required to comply again with the procedures set forth in this Section 11.1 as if it had never given an Offer
Notice. 
 11.1.5 . Change of Control. For the avoidance of doubt, the provisions of this Section 11.1 [***].

 11.2 . BioAmber Drag-Along Right. 
 11.2.1 . Drag-Along Right. In the event that (i) any of the BioAmber Parties undergoes a Change of Control or (ii) BioAmber Lux (or any Permitted Transferee thereof) Transfers its Shares
to a Person other than a Permitted Transferee pursuant to Section 11.1 (each of the events described in clauses (i) and (ii) above, a “BioAmber Triggering Event”), BioAmber shall have the right (the
“Drag-Along Right”) to require Mitsui to sell all (but not less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) to the acquirer of the applicable assets/interests (the “Third Party
Acquirer”) at a purchase price in cash equal to [***] of the aggregate amount of Mitsui’s equity contributions to the Company as of the closing date of such purchase; provided, that the Drag-Along Right shall expire and no
longer apply [***], the “Drag-Along Expiration Date”). 
 11.2.2 . Exercise of Drag-Along Right.
In order to exercise its Drag-Along Right, BioAmber shall, at least [***] days prior to the closing or consummation of the applicable BioAmber Triggering Event, provide written notice to Mitsui of its exercise of the Drag-Along Right (in addition to
the BioAmber Triggering Event Notice referred to below). Subject to Section  

  
 - 24 -

 tk-420278 
 *
Confidential treatment requested 

 
11.4, the closing of the purchase by the Third Party Acquirer of Mitsui’s Shares pursuant to BioAmber’s exercise of the Drag-Along Right (including the payment in full of the
applicable purchase price to Mitsui) shall occur, subject to obtaining any required Consents, simultaneously with the closing or consummation of the applicable BioAmber Triggering Event. 

11.3 . Mitsui Co-Sale Right. 
 11.3.1 . BioAmber Triggering Event Notice. BioAmber shall provide to Mitsui written notice of any BioAmber Triggering Event at least [***] days prior to the closing or consummation of such BioAmber
Triggering Event (the “BioAmber Triggering Event Notice”). The BioAmber Triggering Event Notice shall set forth a description of the material terms of the BioAmber Triggering Event to which it relates, including the nature of
the transaction, purchase price, expected closing date and other relevant terms and conditions. 
 11.3.2 . Co-Sale
Right. Mitsui shall have the right (the “Co-Sale Right”), by providing written notice to BioAmber within [***] days after its receipt of the BioAmber Triggering Event Notice, to require the applicable Third Party Acquirer
(or, at Mitsui’s option, BioAmber) to purchase all (but not less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof), simultaneously with the closing or consummation of the applicable BioAmber Triggering Event, at a
purchase price in cash equal to: 
 (x) if the BioAmber Triggering Event occurs prior to the Drag-Along
Expiration Date, [***]; or 
 (y) if the BioAmber Triggering Event occurs on or after the Drag-Along Expiration
Date, [***]. 
 11.3.3 . Closing. Subject to Section 11.4, the closing of the purchase by such Third Party
Acquirer (or BioAmber, if applicable) of the Shares held by Mitsui (and any Permitted Transferee thereof) pursuant to the exercise of the Co-Sale Right (including the payment in full of the applicable purchase price to Mitsui or its applicable
Permitted Transferee) shall occur, subject to obtaining any required Consents, simultaneously with the closing or consummation of the applicable BioAmber Triggering Event. 
 11.3.4 . BioAmber Parties’ Covenant. If Mitsui exercises its Co-Sale Right, each of the BioAmber Parties (i) shall use its reasonable best efforts to cause the applicable Third Party
Acquirer to purchase the Shares held by Mitsui (and any Permitted Transferee thereof) in accordance with the provisions of this Section 11.3 and (ii) shall not, to the extent it is within its control, close or otherwise consummate
the transaction constituting the BioAmber Triggering Event in respect of which Mitsui exercised its Co-Sale Right unless and until such Third Party Acquirer has purchased the Shares held by Mitsui (and any Permitted Transferee thereof) as provided
herein. 
 11.4 . Terms of Mitsui Share Transfer. The terms and conditions of any Contract pursuant to which Mitsui may
Transfer its Shares pursuant to Section 11.2 or 11.3 shall be reasonably satisfactory to Mitsui, it being understood that neither Mitsui nor any Affiliate thereof shall be required under any such Contract to agree to any
obligation or assume any liability (including making any representation or warranty) that is not specifically related to its ownership of Shares subject to such Transfer. 

  
 - 25 -

 tk-420278 
 *
Confidential treatment requested 

	12.	PUT/CALL OPTIONS 

 12.1
Put/Call Option. In the event that Mitsui’s Pro Rata Share falls below [***], (x) Mitsui shall have the right to sell to BioAmber Lux, and (y) BioAmber Lux shall have the right to purchase from Mitsui, all (but no less than
all) of the Shares held by Mitsui (and any Permitted Transferee thereof) in either case at a purchase price in cash equal to [***]. 
 12.2 . Mitsui Put Option. In the event that (i) BioAmber and Mitsui are unable to agree on the making of any payment by the Company in respect of the EPC Contract, which payment, together with
all other payments made or agreed to be made by the Company under the EPC Contract, would exceed [***], and (ii) pursuant to Section 8.1.2, BioAmber Lux unilaterally approves the making of such payment by the Company, Mitsui shall
have the right to require that BioAmber Lux purchase all (but no less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) at a purchase price in cash equal to [***]. 

12.3 . Exercise of Options; Closing. To exercise its sale or purchase rights under Section 12.1 or 12.2, as
applicable, a Shareholder shall, within [***] days after the occurrence of the event giving rise to such right, provide to the other Shareholder written notice of such exercise. The closing of any such Transfer of Shares shall occur, subject to
obtaining any required Consents, within [***] days after the date the applicable Shareholder delivered to the other Shareholder the notice referred to in the preceding sentence. 

 

	13.	CLOSING OF SHARE TRANSFERS 

13.1 . Time and Place. The closing of any Transfer of Shares pursuant to Section 11.1.3, 11.3.3 (if the
purchaser of such Shares is BioAmber), 12.3, 18.2.3 or 19.3 shall take place at the offices of the Company within the period therefor specified herein or at such other time and place as the parties to such Transfer may agree.

 13.2 . Closing Deliveries. At such closing, (i) the Shareholder that is transferring Shares shall deliver
certificates representing such Shares, accompanied by duly executed instruments of transfer; (ii) the Shareholder purchasing such Shares shall deliver at such closing an amount equal to the aggregate purchase price determined in accordance with
the relevant provisions hereof, by wire transfer in immediately available funds to an account designated by the transferring Shareholder; and (iii) all of the parties to such Transfer shall execute such additional documents as may be necessary
or appropriate to effect such Transfer. 
 13.3 . No Encumbrances; Transfer Taxes. The Shares transferred pursuant to
this Section 13 shall be free and clear of any Encumbrance (other than Encumbrances arising hereunder or attributable to actions by the purchasing Shareholder). Stamp duties or transfer taxes or fees, if any, payable on the Transfer of
any such Shares shall be borne and paid by the party required to pay such duty, taxes or fees in accordance with Applicable Law or as the parties to such Transfer may otherwise agree. 

  
 - 26 -

 tk-420278 
 *
Confidential treatment requested 

 13.4 . Effect of Share Transfer. This Agreement shall cease to have effect with
respect to any Person who is no longer a Shareholder, except that such Person shall continue to be bound, as applicable, by the provisions of this Section 13.4, Sections 15, 17.3, 21, 22 and 23. For the
avoidance of doubt, nothing in this Section 13.4 shall be deemed to release a Person who is no longer a Shareholder from any liability for any breach of this Agreement prior to the date such Persons ceased to be a Shareholder.

  

	14.	PREEMPTIVE RIGHTS, OVERSUBSCRIPTION RIGHTS 

 14.1 . Restrictions. The Company shall not issue any Equity Securities of any type or class (including any Shares) to any Person (the “Proposed Recipient”) unless the
Company has offered each Shareholder in accordance with the provisions of this Section 14, the right to purchase (or have its designated Permitted Transferee purchase) such Shareholder’s Pro Rata Share of such issuance
(“Preemptive Rights”) and the right to oversubscribe (or have its designated Permitted Transferee oversubscribe) if the other Shareholder elects not to purchase its Pro Rata Share of such securities
(“Oversubscription Rights”) for a per unit consideration equal to the per unit consideration to be paid by the Proposed Recipient and otherwise on the same terms and conditions as are offered to the Proposed Recipient
(subject to Section 5.3). The Equity Securities that have not been purchased by a Shareholder (or its designated Permitted Transferee) who fails to exercise its Preemptive Rights or fails to complete the purchase of its Pro Rata Share
shall first be offered to the Shareholder who has exercised its Oversubscription Rights (on behalf of itself or its designated Permitted Transferee) within the Issuance Notice Period (as defined below) pro rata to the number of additional Equity
Securities that such Shareholder (or its designated Permitted Transferee) has agreed to take up above its Pro Rata Share; provided that no Shareholder shall be obligated to purchase more Equity Securities above its Pro Rata Share than such
additional Equity Securities it indicates its agreement to take up under this Section 14.1. The restrictions under this Section 14.1 shall not apply to the following cases or in respect of: (a) any issuance of Equity
Securities in connection with any share split, share dividend or other similar event, (b) subject to Section 8.1.3, any issuance of Equity Securities pursuant to the acquisition of another Person by the Company by consolidation,
merger, purchase of assets or other reorganization in which the Company acquires, in a single transaction or series of related transactions, all or substantially all assets of such other Person, or Control of such other Person ((a) or (b), a
“Permitted Issuance”), or (c) any Defaulting Shareholder (who shall not have Preemptive Rights or Oversubscription Rights). 
 14.2 . Notice. Not less than [***] days prior to a proposed issuance of Equity Securities other than a Permitted Issuance (a “Proposed Issuance”), the Company shall deliver
to each Shareholder written notice of the Proposed Issuance setting forth (a) the number, type and terms of the Equity Securities to be issued, (b) the consideration to be received by the Company in connection with the Proposed Issuance
and (c) the identity of the Proposed Recipient(s). 
 14.3 . Exercise of Rights. Within [***] days following the
receipt of the notice referred to in Section 14.2 (the “Issuance Notice Period”), each Shareholder electing to exercise its rights under this Section 14 shall give written notice to the Company
specifying the number of Equity Securities to be purchased by such Shareholder (or its designated Permitted Transferee), the calculation by such Shareholder of its Pro Rata Share and the identity of any designated Permitted Transferee of such
Shareholder to exercise the rights of such Shareholder under this Section 14. 

  
 - 27 -

 tk-420278 
 *
Confidential treatment requested 

 
Except as provided in the next succeeding sentence, failure by any Shareholder to give such notice within the Issuance Notice Period shall be deemed a waiver by such Shareholder of its rights
under this Section 14 with respect to such Proposed Issuance. If any Shareholder fails to give the notice required under this Section 14.3 solely because of the Company’s failure to comply with the notice provisions of
Section 14.2, then the Company shall not issue Equity Securities pursuant to this Section 14, and if any Equity Securities are purported to be issued, such issuance of securities shall be null and void. 

 

	15.	NON-COMPETE 

 15.1 .
Non-Compete. Mitsui shall not, and shall cause its Affiliates not to, directly or indirectly, compete with the Company or the Initial Plant anywhere in the world for so long as Mitsui holds any Shares of the Company and for a period of [***]
after Mitsui ceases to hold such Shares. For purposes hereof, “compete” means [***]. 
 15.2 .
Exercise of Drag-Along Right. In the event BioAmber exercises its Drag-Along Right, the non-compete period set forth in Section 15.1 shall be reduced to [***]. 

 

	16.	CERTAIN ADDITIONAL AGREEMENTS AND UNDERTAKINGS 

 16.1 . General Shareholder Obligations. Each Shareholder shall comply with the provisions of this Agreement in relation to the Company, shall exercise its rights and powers with respect thereto in
accordance with, and so as to give effect to, this Agreement and shall take all necessary actions to ensure that the Company’s Charter Documents do not, at any time, conflict with the provisions of this Agreement. 

16.2 . Initial Plant. Each party shall, within the scope of its rights and obligations set forth in this Agreement, use its
reasonable best efforts to cause the Initial Plant to be constructed and commissioned with the capacity (including expanded capacity) set forth in Section 3.2 and within the Construction Budget and Schedule. 

16.3 . Certain Operational Matters. 
 16.3.1 Use of Contributions. The Company shall not use any capital or other contributions from any Shareholder for the purposes of directly or indirectly paying or otherwise satisfying any
financial or monetary obligation owed by BioAmber or any BioAmber Affiliate to a third party under any BioAmber IP Agreement, including the payment of any royalties, fees, inventor awards, development costs, or other payments to any owner, inventor,
licensor or developer of, or other third party thereunder, except for any payment related to the Technology License Agreement. 

16.3.2 Exclusive Distributor. Except as otherwise agreed in writing by all the Shareholders, the Company shall not appoint any
Person (other than a party in accordance with this Agreement) as the exclusive distributor in any geography of BSA and/or BDO produced by the Company. Notwithstanding the above, the Company shall be permitted to [***]. BioAmber shall consult Mitsui
prior to the execution of any such exclusive distribution agreements and such agreements shall not be detrimental to the Company’s sales or profitability. 

  
 - 28 -

 tk-420278 
 *
Confidential treatment requested 

 16.3.3 Supply Agreements. Except as expressly provided herein or as otherwise agreed
in writing by all the Shareholders, the Company shall not enter into any Contract that [***]. The foregoing sentence shall not apply to [***].  
 16.3.4 . BioAmber IP. BioAmber shall not, and shall cause its Affiliates not to (a) abandon, dedicate to the public, fail to enforce, or otherwise allow to lapse any BioAmber IP that is a
Registered IP Asset, (b) terminate, willfully or negligently breach, or allow to expire any BioAmber IP Agreement, or (c) take any other action that is reasonably likely to adversely affect or impede the ability of the Company to use and
exploit, in each case as contemplated or otherwise set forth in this Agreement and any Ancillary Agreement, any BioAmber Technology or other Intellectual Property Rights owned, co- or jointly owned, held by or licensed by BioAmber or any BioAmber
Affiliate necessary, useful, or otherwise related to (i) the operation of the Business by the Company, (ii) the building, operation and exploitation of the Additional Plants in accordance with Section 4, or (iii) the
production, use, sale and commercial exploitation of BSA and/or BDO by the parties. 
 16.3.5 . Company Support. If,
during the term of this Agreement, the Company becomes unable to continue to use or practice under any Intellectual Property Rights licensed by BioAmber or any Affiliate thereof to the Company pursuant to the Technology License Agreement in
accordance with the terms thereof as a result of (a) the expiration, termination or breach of any BioAmber IP Agreement by the BioAmber Parties or any BioAmber Affiliate or (b) the abandonment, invalidation or failure to enforce such
Intellectual Property Rights by BioAmber or the applicable licensor of such Intellectual Property Rights, then BioAmber shall use its best efforts to acquire a license to, or otherwise obtain all necessary rights in and to, such Intellectual
Property Rights, or other Intellectual Property Rights as the Shareholders may reasonably agree, to the extent reasonably necessary for the Company to continue to operate the Business, and BioAmber shall promptly license or cause to be licensed to
the Company such Intellectual Property Rights upon the terms and conditions of the Technology License Agreement or as the Shareholders may reasonably agree. 
 16.4 . Additional Agreements. 
 16.4.1 Trademark License Agreement.
As promptly as practicable after the date hereof, BioAmber and Mitsui shall enter into good faith negotiations in respect of a trademark license agreement to be entered into no later than December 31, 2011 between BioAmber, as licensor, and the
Company, as licensee, on terms and conditions to be agreed upon between BioAmber and Mitsui (the “Trademark License Agreement”), which Trademark License Agreement the Company agrees it will duly execute and deliver.

 16.4.2 BioAmber Services Agreement. As promptly as practicable after the date hereof, BioAmber and Mitsui shall enter
into good faith negotiations in respect of a services agreement to be entered into no later than December 31, 2011 between BioAmber and the Company, on terms and conditions to be agreed upon between BioAmber and Mitsui (the “BioAmber
Services Agreement”), which BioAmber Services Agreement the Company agrees it will duly execute and deliver. 

  
 - 29 -

 tk-420278 
 *
Confidential treatment requested 

 16.4.3 Mitsui Services Agreement. As promptly as practicable after the date hereof,
BioAmber and Mitsui shall enter into good faith negotiations in respect of a services agreement to be entered into no later than December 31, 2011 between Mitsui and the Company, on terms and conditions to be agreed upon between BioAmber and
Mitsui (the “Mitsui Services Agreement”), which Mitsui Services Agreement the Company agrees it will duly execute and deliver. 
 16.4.4 Assignment Agreement. As promptly as practicable after the date hereof, BioAmber and Mitsui shall enter into good faith negotiations in respect of an assignment agreement or agreements with
respect to the Supply Contracts to be entered into no later than December 31, 2012 between BioAmber (or its applicable Affiliate, in which case BioAmber shall cause such Affiliate to duly execute and deliver such agreement(s)), as assignor, and
the Company, as assignee, on terms and conditions to be agreed upon between BioAmber and Mitsui (the “Assignment Agreement”), which Assignment Agreement the Company agrees it will duly execute and deliver. 

16.5. Supply Contracts. In the event that BioAmber (or any Affiliate thereof, excluding any Affiliate of BioAmber that exploits or
operates any of the Additional Plants or other plants that produce BSA and/or BDO) enters into any Contract for the supply of BSA and/or BDO to any third party, which Contract is not listed as a Supply Contract in Schedule 16.5 and has not
been assigned to the Company pursuant to the Assignment Agreement, BioAmber shall (or shall cause its applicable Affiliate to), after consultation with Mitsui, with the objective of filling the available capacity of the Initial Plant (if any),
subject to the terms of such Contract (including any applicable geographical restrictions), (i) add such Contract to the list of Supply Contracts set forth in Schedule 16.5 and (ii) assign such Contract to the Company pursuant to an
agreement in form and substance similar to the Assignment Agreement, or as BioAmber and Mitsui may otherwise agree, it being understood that BioAmber shall not assign any such Contract to the Company if by doing so, the capacity of the Initial Plant
would be exceeded at any point during the term of such Contract taking into account the then-existing supply commitments of the Initial Plant. 
 16.5.1. BioAmber Lux’s Obligations. BioAmber guarantees each and every obligation of BioAmber Lux under this Agreement and any Ancillary Agreement to which BioAmber Lux is or hereafter becomes
a party, including each and every representation and warranty of BioAmber Lux hereunder or thereunder, and the full and timely performance of BioAmber Lux’s obligations under this Agreement and such Ancillary Agreements. This is a guarantee of
payment and performance and BioAmber acknowledges and agrees that this guarantee is unconditional. 
  

	17.	REPRESENTATIONS AND WARRANTIES 

 17.1. BioAmber Parties’ Representations and Warranties. The BioAmber Parties hereby jointly and severally represent to Mitsui as follows: 

17.1.1. Organization, Good Standing. Each of the BioAmber Parties and the Company is a corporation or another Entity duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization. 

  
 - 30 -

 tk-420278 
 *
Confidential treatment requested 

 17.1.2. Authority; Binding Nature of Agreements. Each of the BioAmber Parties, the
Company and any other applicable BioAmber Affiliate has, or prior to its execution will have, all requisite corporate (or other applicable Entity) power and authority to execute and deliver this Agreement and each Ancillary Agreement to which it is,
or it will become, a party and to carry out the provisions of this Agreement and such Ancillary Agreements. The execution, delivery and performance by each of the BioAmber Parties, the Company and any other applicable BioAmber Affiliate of this
Agreement and each of the Ancillary Agreements to which it is, or it will become, a party have been, or prior to its execution will be, approved by all requisite action on the part of each such party, its board of directors and shareholders.
BioAmber has delivered, or prior to its execution will deliver, to Mitsui true and complete copies of the resolutions adopted by its board of directors and shareholders approving the execution, delivery and performance of this Agreement, the
Ancillary Agreements to which it is or it will become a party and the transactions contemplated hereby and thereby. Each of the BioAmber Parties and the Company has duly and validly executed and delivered this Agreement and each Ancillary Agreement
to which it is a party, and it (or its applicable Affiliate) will duly and validly execute and deliver each other Ancillary Agreement to which it will become a party. Each of this Agreement and the Ancillary Agreements to which each of the BioAmber
Parties, the Company and any other applicable BioAmber Affiliate is or will become a party constitutes, or upon its execution will constitute, the legal, valid and binding obligation of each such party, enforceable against such party in accordance
with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws and equitable principles related to or limiting creditors’ rights generally and by general principles of equity. 

17.1.3. No Conflicts; Consents. The execution, delivery and performance of this Agreement or any Ancillary Agreement by each of
the BioAmber Parties, the Company and any other applicable BioAmber Affiliate do not and will not (with or without notice or lapse of time) (a) conflict with, violate or result in any breach of (i) any of the provisions of such
party’s Charter Documents; (ii) any resolutions adopted by such party’s shareholders, board of directors or committees thereof; (iii) any Applicable Law; or (iv) any provision of any Contract; (b) give any Governmental
Authority or other Person the right to (i) challenge the transactions contemplated hereby or thereby; (ii) exercise any remedy or obtain any relief under any Applicable Law to which any of the BioAmber Parties, the Company or any other
applicable BioAmber Affiliate, or any of their respective assets, is subject; (iii) declare a default of, exercise any remedy under, accelerate the performance of, cancel, terminate, modify or receive any payment under any Contract; or
(iv) revoke, suspend or modify any Consent; (c) result in the imposition or creation of any Encumbrance upon or with respect to any of its assets or properties; or (d) require any of the BioAmber Parties, the Company or any other
applicable BioAmber Affiliate to obtain any Consent or make or deliver any filing or notice to a Governmental Authority. 

17.1.4. Company. The Charter Documents of the Company, in effect as of the date hereof (after giving effect to the issuance of
Shares to Mitsui and to BioAmber Lux pursuant to the Subscription Agreements), are attached hereto as Annex A. The authorized capital stock of the Company consists of an unlimited number of shares of Class A, B, C, D, E and F. The
Company has issued and outstanding (after giving effect to the Share issuance to Mitsui and to BioAmber Lux pursuant to the Subscription Agreements) One Million (1,000,000) Class A Shares. Other than such Shares, the Company has no other
Equity Interests authorized or outstanding. All issued and outstanding Shares have been duly authorized and validly issued, are fully paid and 

  
 - 31 -

 tk-420278 
 *
Confidential treatment requested 

 
non-assessable, have been issued in compliance with the Company’s Charter Documents and Applicable Law and are free and clear of all Encumbrances (other than, in the case of the Shares
issued to Mitsui pursuant to Mitsui’s Subscription Agreement, any Encumbrances attributable to actions by Mitsui). Except as set forth in this Agreement, there are no (i) outstanding preemptive rights, subscriptions, options, calls,
warrants or other rights to acquire any securities of the Company from the Company, any BioAmber Party or any other Person; (ii) Contracts under which the Company is or may become obligated to sell, issue or otherwise dispose of or redeem,
purchase or otherwise acquire any of its securities; or (iii) stockholder agreements, voting trusts or other Contracts that may affect the exercise of voting or any other rights with respect to the Company’s capital stock to which the
Company or any BioAmber Affiliate is a party. Since its formation until the Share issuance to Mitsui and BioAmber Lux pursuant to the Subscription Agreements, the Company has at all times been a wholly owned direct subsidiary of BioAmber and
BioAmber Lux. The Company does not own any shares of capital stock or other securities of, or Control, any other Entity. The Company has not engaged in any business other than the Business, and to date the Company has not had any material business
operations. 
 17.1.5. No Proceedings. There is no Proceeding pending or, to the BioAmber Parties’ knowledge,
threatened against or affecting any of the BioAmber Parties or the Company, any of their respective properties, assets, operations or businesses, or the BioAmber Parties’ or the Company’s respective rights relating thereto, that could
materially and adversely affect the business or operations of any such party (including, in the case of the Company, the Business) or its ability to fulfill its obligations hereunder, and to the BioAmber Parties’ knowledge, no event has
occurred, and no condition or circumstance exists, that might give rise to or serve as a basis for the commencement of any such Proceeding. 
 17.1.6. Supply Contracts. As of the date hereof, neither BioAmber nor any of its Affiliates is a party to any Contract for the supply to third parties of BSA and/or BDO other than the Supply
Contracts. BioAmber has delivered or made available to Mitsui complete and correct copies of each Supply Contract. Each Supply Contract will be validly assigned to the Company pursuant to the Assignment Agreement, except for (and only to the extent
of) any portion of such Supply Contracts that is not related to the supply of BSA and/or BDO (for instance, any portion of such Supply Contracts that relates to strategic collaboration with third parties involving, without limitation, the
development of application or derivative products, would not be so assigned to the Company). Each Supply Contract is currently valid and in full force and effect, and, after giving effect to its assignment to the Company pursuant to the Assignment
Agreement, will be enforceable by the Company in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws and equitable principles related to or limiting creditors’ rights
generally and by general principles of equity. Neither BioAmber nor any Affiliate thereof is in breach or default under any Supply Contract. To the knowledge of the BioAmber Parties, no event has occurred, and no circumstance or condition exists, in
respect of the Supply Contracts, that is reasonably likely to (with or without notice or lapse of time) (a) result in a violation or breach of any provision of any Supply Contract; (b) give any Person the right to declare a default or
exercise any remedy under any Supply Contract; (c) give any Person the right to accelerate the maturity or performance of any Supply Contract or to cancel, terminate or modify any Supply Contract; or (d) otherwise materially and adversely
affect the Company or its Business. Neither BioAmber nor any Affiliate thereof has waived any of its rights under any Supply Contract. To the knowledge of the BioAmber Parties, no counterparty to any Supply Contract is in breach or default under
such Supply Contract. 

  
 - 32 -

 tk-420278 
 *
Confidential treatment requested 

 17.1.7. Governmental Approvals. Prior to the commencement of construction of the
Initial Plant, the Company will have all Governmental Approvals set forth in Schedule 17.1.7, which are the Governmental Approvals necessary or required in connection with the ownership and use of its properties and assets and the operation
of the Business (including the construction of the Initial Plant as contemplated hereby). The Company has made all filings with, and given all notifications to, all Government Authorities as required by Applicable Law. Prior to the commencement of
construction of the Initial Plant, each such Governmental Approval will be valid and in full force and effect. 
 17.1.8.
Government Finance Agreements. The Company has entered into the financing agreements to finance the construction of the Initial Plant, with the respective Governmental Authorities and for the aggregate amounts, set forth in Schedule
17.1.8 (collectively, the “Government Finance Agreements”). BioAmber has delivered or made available to Mitsui complete and correct copies of each Government Finance Agreement. Each of the Government Finance Agreements
listed under subsection A) of Schedule 17.1.8 is currently valid and in full force and effect and each of the Government Finance Agreements listed under subsection B) of Schedule 17.1.8, once signed by the relevant parties, will be valid and in full
force and effect. None of the BioAmber Parties has any reason to believe that any of the conditions to the financing contemplated by any such Government Finance Agreement will not be satisfied or that such financing will not be available to the
Company on a timely basis to finance the construction of the Initial Plant as contemplated hereby. 
 17.1.9. Registered IP
Assets; Licensed IP. Schedule 17.1.9 sets forth a complete and correct list of all BioAmber Technology that: (a) are Registered IP Assets, specifying the nature of such item, the jurisdiction in which such item has been issued or
registered (or an application has been filed), registration or application number, and any co- or joint owner; and (b) are Licensed IP, specifying the licensor(s) of the applicable Licensed IP and the nature of the license granted to BioAmber
or its Affiliate(s). 
 17.1.10. BioAmber Technology. Each item of BioAmber Technology set forth in Schedule
17.1.9 that is necessary, useful, or otherwise related to the operation of the Business will be duly and validly licensed by BioAmber Lux to the Company as of the date of this Agreement for use by the Company in connection with the operation of
the Business, all of which rights shall survive unchanged by the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements. Schedule 17.1.9 includes all Intellectual Property Rights owned, used or held for
use or licensed by BioAmber and its Affiliates necessary, useful, or otherwise related to the operation of the Business, and there are no other Intellectual Property Rights that are material to or necessary for the operation of the Business by the
Company as contemplated or otherwise set forth in this Agreement. BioAmber and BioAmber Lux have obtained all permissions, Consents, licenses and other grant of rights necessary to license the foregoing Intellectual Property Rights in and to such
BioAmber Technology to the Company for use in connection with the operation of the Business. 

  
 - 33 -

 tk-420278 
 *
Confidential treatment requested 

 17.1.11. BioAmber IP Agreements. (a) BioAmber, BioAmber Lux and all BioAmber
Affiliates are in full compliance with the terms and conditions of the BioAmber IP Agreements, (b) BioAmber has a valid license to use the Licensed IP, and the right to duly and validly sublicense its rights in and to such Licensed IP to
BioAmber Lux, (c) BioAmber Lux has the right to duly and validly grant a license to use and exploit such Licensed IP to the Company in accordance with the terms of this Agreement and the Ancillary Agreements, and (d) no BioAmber Party has
knowledge of any facts which are reasonably likely to adversely affect or impede the ability of the Company to use and exploit any Licensed IP in connection with the operation of the Business. 

17.1.12. No Infringement; Breach. The BioAmber Technology and operation of the Business by the Company as contemplated or
otherwise set forth in this Agreement and the Ancillary Agreements, does not and will not (i) infringe or misappropriate the Intellectual Property Rights of any third party, (ii) result in the breach of any BioAmber IP Agreement, or
(iii) violate any Applicable Laws. Neither BioAmber nor any BioAmber Affiliate has received written notice from any third party (including an “invitation to take a license” from any third party) claiming that the use by BioAmber or
any BioAmber Affiliate of any BioAmber Technology, or the exercise by BioAmber of any BioAmber Affiliate of any rights and licenses granted to BioAmber or any BioAmber Affiliate under any BioAmber IP Agreement, infringes or misappropriates any
Intellectual Property Rights of any third party (nor does any of the BioAmber Parties have knowledge of any basis therefor). 

17.1.13. No Infringement of BioAmber IP. To the knowledge of the BioAmber Parties, no Person is infringing or misappropriating any
BioAmber IP. 
 17.1.14. No Development of Biocatalysts. BioAmber is not itself or with or through third parties
currently engaged in the development of biocatalysts other than E. coli (including but not limited to the genetic modification or the optimization of fermentation conditions) [***], including any biocatalysts developed, licensed or funded by
BioAmber or to which BioAmber has secured a future right or right of first refusal through any payments to third parties related thereto, except for any development activities (a) [***] or (b) [***]. As of the date hereof, [***] pursuant
to (b) above (i) are limited to (x) [***] and (y) [***], and (ii) [***]. 
 17.1.15. BioAmber IP
Agreements; BioAmber Technology. None of the execution, delivery and performance of this Agreement and the Ancillary Agreements, and the consummation of the transactions contemplated hereby and thereby, will (a) conflict with, result in a
breach of, modify, accelerate or terminate, or give rise to a right to modify, accelerate or terminate, any BioAmber IP Agreement; (b) cause the forfeiture or termination or give rise to a right of forfeiture of, termination of, or result in
the diminishment in the value of or any loss of BioAmber’s, BioAmber Lux’s or the Company’s right to use or license, as applicable, any BioAmber Technology; (c) require the Company to seek the Consent under, or to obtain an
additional license of rights with respect to, any BioAmber IP Agreement or BioAmber Technology, including with respect to any restrictions or limitations on the production or sale of BSA and/or BDO in any geography; or (d) result in Mitsui or
the Company (i) granting to any third party any right or license to any of the BioAmber Technology, (ii) granting to any third party any right or license to any Intellectual Property Rights of Mitsui or any of its Affiliates,
(iii) being bound by, or subject to, any non-compete or other restriction on the operation or scope of its business, or (iv) being obligated to pay any royalties or other amounts to any third party, in each case other than as a result of
Contracts to which Mitsui or any of its Affiliates, and not the Company, is a party. 

  
 - 34 -

 tk-420278 
 *
Confidential treatment requested 

 17.1.16. Environmental Matters. The site at which the Initial Plant will be located
is described in Schedule 17.1.16 (the “Initial Plant Site”). The current owner of the Initial Plant Site conducted a Phase I environmental assessment of the Initial Plant Site in 2008, a copy of which assessment has
been made available to Mitsui. In addition, jointly with the owner of the Initial Plant Site, BioAmber has conducted a Phase II environmental assessment of the Initial Plant Site, a copy of which assessment has been made available to Mitsui. Such
Phase II environmental assessment has revealed no material environmental conditions relating to the Initial Plant Site, including the presence of any Hazardous Materials thereat, or any other environmental issues that could materially and adversely
affect the Company or the Business. To the BioAmber Parties’ knowledge, there is no Proceeding pending or threatened involving any environmental issues at the Initial Plant Site. 

17.2 . Mitsui’s Representations and Warranties. Mitsui hereby represents to the BioAmber Parties as follows: 

17.2.1. Organization; Valid Existence. Mitsui is a corporation duly organized and validly existing under the laws of Japan.

 17.2.2. Authority; Binding Nature of Agreements. Mitsui has, or prior to its execution will have, all requisite
corporate power and authority to execute and deliver this Agreement and each Ancillary Agreement to which it is, or it will become, a party and to carry out the provisions of this Agreement and such Ancillary Agreements. The execution, delivery and
performance by Mitsui of this Agreement and the Ancillary Agreements to which it is, or it will become, a party have been, or prior to its execution will be, approved by all requisite action on the part of each such party. Mitsui has duly and
validly executed and delivered this Agreement and each Ancillary Agreement to which it a party, and it will duly and validly execute and deliver each other Ancillary Agreement to which it will become a party. Each of this Agreement and the Ancillary
Agreements to which Mitsui is or will become a party constitutes, or upon its execution will constitute, the legal, valid and binding obligation of such party, enforceable against each such party in accordance with its terms, except as may be
limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws and equitable principles related to or limiting creditors’ rights generally and by general principles of equity. 

17.2.3. No Conflicts; Consents. The execution, delivery and performance of this Agreement or any Ancillary Agreement by Mitsui do
not and will not (with or without notice or lapse of time) (a) conflict with, violate or result in any breach of (i) any of the provisions of such party’s Charter Documents; (ii) any resolutions adopted by such party’s
shareholders, board of directors or committees thereof; (iii) any Applicable Law; or (iv) any provision of any Contract; (b) give any Governmental Authority or other Person the right to (i) challenge the transactions contemplated
hereby or thereby; (ii) exercise any remedy or obtain any relief under any Applicable Law to which Mitsui, or any of its assets, is subject; (iii) declare a default of, exercise any remedy under, accelerate the performance of, cancel,
terminate, modify or receive any payment under any Contract; or (iv) revoke, suspend or modify any Consent; (c) result in the imposition or creation of any Encumbrance upon or with respect to any of its assets or properties; or
(d) require Mitsui to obtain any Consent or make or deliver any filing or notice to a Governmental Authority. 

  
 - 35 -

 tk-420278 
 *
Confidential treatment requested 

 17.2.4. No Proceedings. There is no Proceeding pending or, to Mitsui’s
knowledge, threatened against or affecting Mitsui, any of its properties, assets, operations or businesses, or its rights relating thereto, that could materially and adversely affect the business or operations of such party or its ability to fulfill
its obligations hereunder, and to Mitsui’s knowledge, no event has occurred, and no condition or circumstance exists, that might give rise to or serve as a basis for the commencement of any such Proceeding. 

17.3. Survival of Representations and Warranties. The respective representations and warranties of the applicable parties set
forth in this Section 17 shall survive indefinitely and continue in effect notwithstanding the termination of this Agreement. 
  

	18.	DEFAULT 

 18.1. Events
of Default. 
 18.1.1. Events of Default. Each of the following events constitutes an “Event of
Default” with respect to a Shareholder, it being understood that if such Shareholder is (x) BioAmber Lux or a Permitted Transferee thereof (other than BioAmber), the occurrence of any such event with respect to BioAmber shall
constitute an Event of Default with respect to BioAmber Lux or such Permitted Transferee, as applicable, or (y) a Permitted Transferee of Mitsui, the occurrence of any such events with respect to Mitsui shall constitute an Event of Default with
respect to such Permitted Transferee: 
 (a) such Shareholder makes a general assignment for the benefit of
creditors; 
 (b) the appointment of a conservator, custodian, receiver, trustee or similar official for such
Shareholder or its assets; 
 (c) any voluntary or involuntary bankruptcy, insolvency, reorganization, debt
adjustment, dissolution, liquidation, receivership or other debt relief proceedings is commenced (and not dismissed or otherwise terminated) in respect of such Shareholder (excluding, for the avoidance of doubt, any bona fide corporate
reorganization not involving debt relief or insolvency issues); or 
 (d) such Shareholder materially breaches
this Agreement or any of the Ancillary Agreements and such breach, if of a nature that can be cured, remains uncured thirty (30) days after such Shareholder received notice thereof from the other Shareholder. 

18.1.2. Suspension of Certain Rights Upon an Event of Default. In addition to other limitations on a Defaulting Shareholder’s
rights set forth elsewhere in this Agreement, upon the occurrence of an Event of Default and for so long as such Event of Default has not been remedied to the reasonable satisfaction of the Shareholder other than the Defaulting Shareholder, and
notwithstanding anything to the contrary set forth herein, (i) the presence of the Defaulting Shareholder shall not be required to constitute quorum at any Shareholders’ meeting; (ii) the Defaulting Shareholder shall not have the
right to vote in respect of any matter reserved for the approval of the Shareholders pursuant to Section 8.1.2 or 8.1.3 (which matter may be approved solely by the non-Defaulting Shareholder); (iii) the presence of the
Defaulting Shareholder’s 

  
 - 36 -

 tk-420278 
 *
Confidential treatment requested 

 
nominee(s) to the Board shall not be required to constitute quorum at any Board meeting; (iv) the Defaulting Shareholder’s nominee(s) to the Board shall not have the right to vote in
respect of any matter subject to Board approval (which matter may be approved solely by the non-Defaulting Shareholder’s nominee(s) to the Board); and (v) the Defaulting Shareholder shall have no right to receive dividends or other
distributions from the Company. 
 18.2. Option to Buy/Sell Upon an Event of Default. 

18.2.1. Mitsui Event of Default. If an Event of Default occurs and is continuing and Mitsui is the Defaulting Shareholder,
BioAmber Lux shall have the right to purchase the Shares held by Mitsui (and any Permitted Transferee thereof) at a purchase price equal to [***] of the lesser of (i) [***] and (ii) [***], in each case calculated on the date
BioAmber Lux delivered the Default Option Exercise Notice. 
 18.2.2. BioAmber Event of Default. If an Event of Default
occurs and is continuing and a BioAmber Party is the Defaulting Shareholder, Mitsui shall have the right to sell to BioAmber Lux the Shares held by Mitsui (and any Permitted Transferee thereof) at a purchase price equal to [***] of the
greater of (i) [***] and (ii) [***], in each case calculated on the date Mitsui delivered the Default Option Exercise Notice. 
 18.2.3. Exercise of Rights; Closing. To exercise its purchase or sale right under Section 18.2.1 or 18.2.2, as applicable, the non-Defaulting Shareholder shall provide notice
thereof to the Defaulting Shareholder (the “Default Option Exercise Notice”). The closing of any such Transfer of Shares shall occur, subject to obtaining any required Consents, within [***] days after the date the applicable
Shareholder delivered to the Defaulting Shareholder the Default Option Exercise Notice. 
  

	19.	DISSOLUTION 

 19.1.
Dissolution Events. In the event that (i) the Operational Date does not occur by [***]; (ii) the cumulative losses of the Company exceed [***] of its paid-in capital; (iii) the Company earns no after-tax profit in [***]
consecutive Financial Years; (iv) the Company becomes unable to pay its debts generally as they become due or subject to a bankruptcy, insolvency or other analogous proceeding; or (v) there occurs any other dissolution event in respect of
the Company provided for under Applicable Law (each, a “Dissolution Event”), each Shareholder shall have the right, by providing written notice to the other Shareholder (the “Dissolution Notice”), to
cause the Company to be dissolved and liquidated, whereupon the Shareholders shall cooperate and take all necessary steps for dissolving and liquidating the Company in accordance with Applicable Law and terminating their respective contractual
obligations therewith. 
 19.2. Distribution of Remaining Assets. Unless otherwise agreed by the Shareholders, any assets
and property of the Company remaining after such liquidation shall be allocated and distributed to the Shareholders in accordance with their then respective Pro Rata Shares. 
 19.3. Right to Prevent Dissolution. Notwithstanding the provisions of Section 19.1, the Company shall not be so dissolved and liquidated if, upon the occurrence of a Dissolution Event,
(i) a Shareholder opposes the dissolution and liquidation requested by the other Shareholder and 

  
 - 37 -

 tk-420278 
 *
Confidential treatment requested 

 
(ii) such Shareholder opposing the dissolution and liquidation agrees to purchase the Shares held by the other Shareholder (and any Permitted Transferee thereof) at a purchase price equal to
[***] calculated on the date of such agreement. The closing of such Transfer of Shares shall occur, subject to obtaining any required Consents, within [***] days after the date of such agreement. 

 

	20.	TERMINATION 

 20.1.
Termination of the Agreement. This Agreement shall become effective from its date and shall continue in effect until (a) any date agreed upon in writing by all of the parties, (b) the Company is liquidated, dissolved or wound-up or
(c) there is only one (1) Shareholder. 
 20.2. Consequences of Termination. If this Agreement is terminated
pursuant to Section 20.1, this Agreement shall have no further force and effect, except that the parties shall continue to be bound, as applicable, by the provisions of this Section 20, Sections 8.2.13, 15,
17.3, 21, 22 and 23. For the avoidance of doubt, nothing in this Section 20 shall be deemed to release any party from any liability for any breach of this Agreement prior to the effective date of such
termination. 
  

	21.	INDEMNIFICATION 

 21.1.
General Indemnification. Subject to, in the case of the Company, any applicable indemnification obligation of the Company to the Directors pursuant to the Indemnification Agreement, each party shall indemnify, defend and hold harmless each
other party, its Affiliates and its and their respective directors, officers, employees, agents and advisors from and against any Loss arising out, relating to or resulting from any breach by such party of any representation or warranty, or
covenant, agreement or undertaking, contained in this Agreement. 
 21.2. IP Indemnification. BioAmber, on behalf of
itself and its Affiliates, shall indemnify, defend and hold harmless each of Mitsui and the Company, its respective Affiliates and its and their respective directors, officers, employees, agents and advisors from and against any Loss arising out,
relating to or resulting from the Company’s use of, and the exercise of any rights licensed by BioAmber or any Affiliate thereof to the Company in and to, any BioAmber Technology, including with respect to the operation of the Business
generally and the production, sale and use of BSA and/or BDO. 
 21.3. No Consequential Damages. Notwithstanding anything
to the contrary in this Section 21, to the maximum extent permitted by Applicable Law, no party shall be liable under this Agreement to any Person for any indirect, incidental, punitive, exemplary or consequential damages; provided,
however, that the foregoing shall not be construed to preclude recovery by any party in respect of Losses incurred from third party claims. 
  

	22.	DISPUTE RESOLUTION 

 22.1.
Escalation Procedure. Any dispute, controversy, claim or disagreement between or among any parties (each, a “Dispute”) arising out of this Agreement, its interpretation or the performance by any party of its
obligations hereunder, including any questions regarding the existence, validity or termination hereof, shall be resolved pursuant to this Section 22. For clarity, any disagreement related to the matters set forth in
Section 8.1.2 shall be subject to the BioAmber Right to Approve set forth in the provision included in such Section. Any Dispute that the relevant 

  
 - 38 -

 tk-420278 
 *
Confidential treatment requested 

 
parties are unable to resolve through amicable negotiations shall be submitted by the parties for further review and discussion to designated senior representatives of each such party with
authority to reach an agreement in connection with such Dispute. Such designated senior representatives shall meet or otherwise confer as promptly as practicable, and endeavor in good faith to resolve the Dispute. If such designated senior
representatives are unable to reach an agreement to resolve the Dispute within ten (10) days after their initial meeting, then the Dispute shall be resolved pursuant to Section 22.2  

22.2. Arbitration. 
 22.2.1. Rules. Any Dispute that is not resolved pursuant to Section 22.1 shall be finally settled by binding arbitration administered by the ICC, in accordance with the ICC Rules of
Arbitration (the “ICC Rules”) in effect at the time of the arbitration, except as they may be modified herein or by agreement of all the parties to the Dispute. Each party to the arbitration shall be deemed to be an
“Arbitration Party” for purposes of this Section 22.2. 
 22.2.2. Place; Language.
The place of arbitration shall be New York, New York, and the proceedings shall be conducted in the English language. 
 22.2.3.
Tribunal. The arbitration shall be conducted by three arbitrators (such panel of arbitrators, the “Tribunal”). 
 22.2.4. Arbitrators–Two Arbitration Parties. If there are two Arbitration Parties to the arbitration, each Arbitration Party shall nominate one (1) arbitrator within thirty (30) days
after delivery of the “Request for Arbitration” (as defined in the ICC Rules). In the event an Arbitration Party fails to nominate an arbitrator within this time period, then upon request of either Arbitration Party, such arbitrator shall
instead be appointed by the ICC within thirty (30) days of receiving such request. The two (2) arbitrators appointed in accordance with the above provisions shall nominate the third arbitrator within thirty (30) days of the
appointment of the second arbitrator. If the first two appointed arbitrators fail to nominate a third arbitrator within this time period, then upon request of either Arbitration Party, the third arbitrator shall be appointed by the ICC. The third
arbitrator shall serve as chairman of the Tribunal. 
 22.2.5. Arbitrators–More Than Two Arbitration Parties. If
there are more than two (2) Arbitration Parties to the arbitration, they shall in good faith attempt to group themselves into a “Petitioning Party” and a “Defending Party” for purposes of
selecting arbitrators. Each of the Petitioning Party and the Defending Party shall nominate one arbitrator within thirty (30) days after delivery of the Request for Arbitration. The two (2) arbitrators appointed in accordance with the
above provisions shall nominate the third arbitrator within thirty (30) days of their appointment. If the first two appointed arbitrators fail to nominate a third arbitrator within this time period, then upon request of any party to the
arbitration, the third arbitrator shall be appointed by the ICC. The third arbitrator shall serve as chairman of the Tribunal. If it shall not be possible to form a Petitioning Party or a Defending Party, as the case may be, or if the Petitioning
Party or the Defending Party, as the case may be, fails to select an arbitrator in accordance with this Section 22.2.5, then, in accordance with Article 10(2) of the ICC Rules, the ICC shall appoint each member of the Tribunal and shall
designate one of them to act as chairman. 

  
 - 39 -

 tk-420278 
 *
Confidential treatment requested 

 22.2.6. Provisional Remedies. By agreeing to arbitration, the Arbitration Parties do
not intend to deprive any court of competent jurisdiction of its ability to issue any form of provisional remedy, including a preliminary injunction or attachment in aid of the arbitration, or to order any interim or conservatory measure (each, a
“Provisional Remedy”). A request for such Provisional Remedy by a party to a court shall not be deemed a waiver of this agreement to arbitrate. Notwithstanding the foregoing, once the selection of the arbitrators is complete
in accordance with this Section 22.2, the continuation, termination, amendment, or modification of any Provisional Remedy shall be determined by the arbitrators and, after an arbitration hearing is commenced, the action, suit, or
proceeding commenced in such court seeking such Provisional Remedy shall be dismissed by the stipulation of all parties to the relevant Dispute. In the event that any such party fails to stipulate to the dismissal of the action, the parties agree
that the arbitrators may submit a stipulation dismissing the action. The arbitrators may conduct any hearings or order any discovery they deem necessary to properly review the Provisional Remedy. This Section 22.2.6 shall be specifically
enforceable by each party. 
 22.2.7. Award. The award rendered by the arbitrators shall be final and binding on the
Arbitration Parties. Judgment on the award may be entered and the award may be enforced in any court of competent jurisdiction. 

22.2.8. Confidentiality. Any arbitration hereunder shall be confidential, and the Arbitration Parties and their agents and the
arbitrators shall not disclose to any non-Arbitration Party the subject of the arbitration, any information about the arbitration or the substance of the proceedings thereunder except as may be required by Applicable Law, for insurance purposes, or
as necessary to enforce this agreement to arbitrate or any award hereunder or in connection with a request for any Provisional Remedy. 
  

	23.	MISCELLANEOUS 

 23.1.
No Partnership. The Shareholders expressly intend not to form a partnership hereby, either general or limited, under any jurisdiction’s partnership law. The Shareholders do not intend to be partners one to another, or partners as to any
third party, or create any fiduciary relationship among themselves, solely by virtue of their status as Shareholders. 
 23.2.
Discrepancies. If there is any discrepancy between any provision of this Agreement and any provision of the Company’s Charter Documents, the provisions of this Agreement shall prevail as between the Shareholders, and the parties shall
procure that the Company’s Charter Documents are promptly amended, to the extent permitted by Applicable Law, in order to conform to this Agreement. 
 23.3. Notices. 
 23.3.1. Notices. Each notice, demand or other
communication given or made under this Agreement shall be in writing, in English and delivered or sent to the relevant party at its address or fax number set out below (or such other address or fax number as the addressee has by five
(5) days’ prior written notice specified to the other parties). Any notice, demand or other communication so addressed to the relevant party shall be deemed to have been delivered, (a) if delivered in person or by messenger, when
proof of delivery is obtained by the delivering party; (b) if sent by post within the same country, on the third (3rd) day following posting, and if sent by post to another country, on the fifth (5th) day following posting; and
(c) if given or made by fax, upon dispatch and the receipt of a transmission report confirming dispatch. 

  
 - 40 -

 tk-420278 
 *
Confidential treatment requested 

 23.3.2. Addresses; Fax Numbers. The initial address and facsimile for each party for
the purposes of this Agreement are: 
 (1) for Mitsui: 

Address: [***] 
 (2) for BioAmber: 
 Address: 1250 Rene-Levesque West, Suite 4110

      Montreal, Quebec, Canada, H3B 4W8 

     Attention: Jean-François Huc, President & CEO 

[***] 
 (3) for the Company: 
 Address: 1250 Rene-Levesque West, Suite 4110

      Montreal, Quebec, Canada, H3B 4W8 

     Attention: Jean-François Huc, President & CEO 

[***] 
 23.4. Expenses. Except as otherwise noted herein, each Shareholder shall bear the expenses incurred by it in connection with the negotiation and execution of this Agreement and the performance of
its obligations hereunder. 
 23.5. Entire Agreement. This Agreement, the Exhibits, the Schedules and the Ancillary
Agreements constitute the entire agreement among the parties relating to the subject matter hereof and thereof and supersede all prior oral and written understandings, all contemporaneous oral negotiations and discussions, and all other writings and
agreements relating to the subject matter hereof and thereof. 
 23.6. Counterparts. This Agreement may be executed in
one or more counterparts, with the same effect as if the parties had signed the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.
Delivery of a signature page by facsimile or electronic means shall have the same effect as the delivery of a manually executed original thereof. 
 23.7. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles or rules of conflict of laws to
the extent such principles or rules would require or permit the application of the laws of another jurisdiction. 

  
 - 41 -

 tk-420278 
 *
Confidential treatment requested 

 23.8. Severability. Each and every obligation under this Agreement shall be treated
as a separate obligation and shall be severally enforceable as such. If a term of this Agreement is or becomes illegal, invalid or unenforceable in any respect under any jurisdiction, that shall not affect (a) the legality, validity or
enforceability in that jurisdiction of any other term of this Agreement or (b) the legality, validity or enforceability in any other jurisdictions of that or any other term of this Agreement. If a term of this Agreement is or becomes illegal,
invalid or unenforceable in any respect under any jurisdiction, it shall be replaced by a mutually acceptable provision, which being valid, legal, enforceable and in compliance with applicable government policy comes closest to the intention of the
parties underlying such illegal, invalid or unenforceable provision. 
 23.9. Survival of Rights, Duties and Obligations.
Termination of this Agreement for any cause shall not release any party from any liability which at the time of termination has already accrued to any other party or which thereafter may accrue in respect of any act or omission prior to such
termination, nor shall any such termination hereof affect in any way the survival of and right, duty or obligation of any party which is expressly stated elsewhere in this Agreement to survive termination hereof or which by its nature shall survive
the termination of this Agreement. 
 23.10. Specific Performance. The parties acknowledge that it may be impossible to
measure in money the damages that would be suffered by a party by reason of the failure by any of the other parties to perform any of its obligations hereunder, and that irreparable damage may occur in the event that any of the provision of this
Agreement is not performed in accordance with its specific terms or otherwise breached. Therefore, if a party shall institute any Proceeding to enforce the provisions hereof, a party against whom such Proceeding is brought hereby waives any claim or
defense therein that the other party has an adequate remedy at law. 
 23.11. Assignment. No Shareholder shall assign, or
suffer or permit an assignment (by operation of law or otherwise), of its rights or obligations under or interest in this Agreement without the prior written consent of the other Shareholder and the Company, except to the extent expressly permitted
hereunder, and any purported assignment or other disposition by a Shareholder in violation of this Section 23.11 shall be deemed to be a breach of this Agreement. Subject to the foregoing, this Agreement shall inure to the benefit of and
be binding upon the parties and their respective successors and permitted assigns. 
 23.12. Amendment; Waiver. This
Agreement cannot be amended or otherwise modified nor any performance, term, or condition waived in whole or in part, except by a writing signed by the party against whom enforcement of the amendment, modification or waiver is sought. No delay or
failure on the part of any party in exercising any rights hereunder, and no partial or single exercise thereof, will constitute a waiver of such rights or of any other rights hereunder. Without limiting the foregoing, no waiver by a party of any
breach by any other party of any provision hereof shall be deemed to be a waiver of any subsequent breach of that or any other provision hereof. 
 23.13. Limitation on Rights of Third Parties. This Agreement is entered into among the parties for the exclusive benefit of the parties and their successors and permitted assigns. Except as
otherwise expressly provided herein, this Agreement is not intended for the benefit of any other Person. 

  
 - 42 -

 tk-420278 
 *
Confidential treatment requested 

 23.14. Confidentiality. 

23.14.1. Confidential Information. In order to protect the Confidential Information of any party (a “Disclosing
Party”) that becomes available to any other party (a “Receiving Party”), the Receiving Party agrees that (i) it shall make no use of such Confidential Information except in furtherance of the purposes of,
and as contemplated by, this Agreement, and (ii) it shall not (and it shall cause its Affiliates, directors, officers, employees, agents and representatives not to) without the prior written consent of the Disclosing Party, disclose to any
third party Confidential Information of such Disclosing Party, so long as such Receiving Party is a Shareholder and for a period of [***] thereafter or, in the case of the Company, so long as it remains in existence; provided, however,
that: 
 (a) a Receiving Party may disclose Confidential Information to those of its Affiliates, directors,
officers, employees, agents and representatives who have a need to know such Confidential Information in relation to the matters contemplated hereby and who are under obligations of confidentiality and non-use consistent with those set forth herein;
provided that any disclosure of Confidential Information by a party’s Affiliates, directors, officers, employees, agents and representatives that is not permitted by this Section 23.14 shall be a breach by such party of this
Section 23.14; 
 (b) disclosure of Confidential Information is permitted to the extent that such
disclosure is required pursuant to Applicable Law; provided however, that the Receiving Party shall promptly notify the Disclosing Party in writing of the existence of any such requirement and reasonably cooperate with the Disclosing Party in
seeking an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information; 
 (c) this Section 23.14 shall not apply to any Confidential Information which: 
 i. was in the public domain or the subject of public knowledge at the time of its disclosure; 
 ii. becomes part of the public domain or the subject of public knowledge through no breach by or act of default of the Receiving Party or its representatives, employees or agents; 

iii. is obtained by the Receiving Party from a third party other than in breach of a legal or contractual obligation of
confidentiality owed by such third party to the Disclosing Party in respect thereof, the existence of which obligation was known or should have been known by the Receiving Party; or 

iv. the Receiving Party establishes was independently developed by it without reference to Confidential Information.

 23.15. Advertising; Publicity. Each party agrees not to issue any press release or otherwise make any public
disclosure with respect to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby without the prior written approval of the other parties, unless, and only to the extent, required pursuant to Applicable Law
(including the rules of 

  
 - 43 -

 tk-420278 
 *
Confidential treatment requested 

 
any stock exchange to which such party or any Affiliate thereof may be subject), in which case, to the extent practicable, the party intending to make such disclosure shall give advance notice
thereof to the other parties. Notwithstanding the foregoing, it is the parties’ intent to issue a press release following the signing of this Agreement, subject to the parties agreeing to the content of such press release. 

23.16. Subsequent Shareholders. Any Person not a signatory to this Agreement who hereafter becomes a Shareholder as provided
hereby shall be bound by all of the terms and provisions, and shall be entitled to all the benefits and privileges, of this Agreement. Before any Person not a signatory to this Agreement, including any Person to whom transfers of Shares may be made
hereunder, may be entitled to be a Shareholder, such Person shall be required to execute and deliver to the Company an agreement, in form and substance reasonably acceptable to the Company and the Shareholders (a “Joinder
Agreement”) pursuant to which such Person agrees to be bound by all of the terms and conditions of this Agreement, and the failure of any such Person to do so shall preclude such Person from becoming a Shareholder. 

[Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 - 44 -

 tk-420278 
 *
Confidential treatment requested 

 IN WITNESS WHEREOF, the parties have signed this Joint Venture Agreement as of the date
first written above. 
  

					
	BIOAMBER INC.
		
	By:	 	/s/ Jean-François Huc
		 	Name:	 	Jean-François Huc
		 	Title:	 	President & Chief Executive Officer

  

					
	BIOAMBER INTERNATIONAL S.À.R.L.
		
	By:	 	/s/ Jean-François Huc 
		 	Name:	 	J.F. Huc
		 	Title:	 	Manager

 
					
		
	By:	 	/s/ [***]
		 	Name:	 	[***]
		 	Title:	 	[***]

  

					
	MITSUI & CO., LTD.
		
	By:	 	/s/ [***]
		 	Name:	 	[***]
		 	Title:	 	[***]

 
					
		
	By:	 	 
		 	Name:	 	[***]
		 	Title:	 	[***]

  

					
	BLUEWATER BIOCHEMICALS INC.
		
	By:	 	/s/ Jean-François Huc
		 	Name:	 	Jean-François Huc
		 	Title:	 	President

  
 * Confidential
treatment requested 

 ACKNOWLEDGEMENT AND ACCEPTANCE 

The undersigned hereby acknowledges having taken cognizance of this Agreement and accepts the duties incumbent upon it pursuant to Section 1.2.6 of
said Agreement. 
  

					
	Boivin Desbiens Senécal, g.p.
		
	By:	 	[***]
	Name:	 	[***]
	Title:	 	[***]

  
 * Confidential
treatment requested 

 Schedule 3.3 
 Construction Budget and Schedule 
 [Attached] 

[*** 2 pages omitted.] 

  
 * Confidential
treatment requested 

 Schedule 5.1 
 Initial Capital Contributions and Pro Rata Shares 
  

											
	 SHAREHOLDER
	 	 FIRST
DISBURSEMENT OF
INITIAL
CAPITAL
CONTRIBUTION
	 	 SHARES OF COMON
STOCK
	  	SUBSEQUENT
DISBURSEMENTS
OF INITIAL
CAPITAL
CONTRIBUTION*	  	SHARES OF
COMMON
STOCK**	  	PRO RATA
SHARE

 [***] 
  
  

	*	Maximum aggregate amounts. The Board may call for lesser amounts in accordance with Sections 5.1.1 and 5.1.2, as applicable. 

	**	Maximum number of shares issuable in respect of maximum aggregate subsequent disbursements of initial capital contribution. Actual number of shares may be
proportionally adjusted (i) if Board calls for lesser amounts of subsequent disbursements of initial capital contribution in accordance with Sections 5.1.1 and 5.1.2, as applicable, and (ii) to account for stock splits, stock
recombinations and similar transactions in respect of the Company’s capital stock. 

  
 * Confidential
treatment requested 

 Schedule 16.5 
 Supply Contracts 
 [***] 

  
 * Confidential
treatment requested 

 Schedule 17.1.7 

List of Governmental Approvals to be obtained 
 prior to the commencement of construction of the Initial Plant 
 [***] 

  
 * Confidential
treatment requested 

 Schedule 17.1.8 

Government Finance Agreements 

A) EXECUTED AGREEMENTS: 
  

			
	 Governmental Authorities
	  	 Amount of the financing

	Her Majesty the Queen in right of the province of Ontario, as represented by the Minister of Economic Development and Trade	  	CAD$15,000,000
	Her Majesty the Queen in right of Canada, as represented by the Minister responsible for Federal Economic Development Agency for Southern Ontario	  	CAD$12,000,000

 B) AGREEMENTS TO BE EXECUTED SHORTLY AFER EXECUTION OF THIS JOINT VENTURE AGREEMENT: 

 

			
	 Governmental Authorities
	  	 Amount of the financing

	Canadian Foundation for Sustainable Development Technology	  	CAD$7,500,000
	Sustainable Chemistry Alliance	  	CAD$500,000

  
 * Confidential
treatment requested 

 Schedule 17.1.9 

List of BioAmber Technology 
 [Attached] 
 [*** 11 pages omitted.] 

  
 * Confidential
treatment requested 

 Schedule 17.1.16 

Site of the Initial Plant located at 1201 Vidal Street, Sarnia, Ontario, Canada 
 [***] 

  
 * Confidential
treatment requested 

 Annex A 
 Charter Documents of the Company 
 [Attached] 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested 

 Schedule / Annexe 

Description of Classes of Shares / Description des categories d’actions 

3. DESCRIPTION OF THE SHARE CAPITAL OF THE CORPORATION 
 The authorized share capital of the Corporation is composed of an unlimited number of Class “A”, “B”, “C”, “D”, “E” and “F” shares, with the
following privileges and restrictions: 
 3.1. CLASS “A” SHARES 
 Holders of Class “A” shares: 
 Vote 

3.1.1. Shall have the right to vote at any meeting of the shareholders of the Corporation. Each Class “A” share confers one (1) vote.

 Dividends 
 3.1.2. Shall have the
right to receive, during each financial year and out of the funds which can legally serve this purpose, a dividend, of which the amount, declaration and payment thereof is left to the discretion of the Directors, subject to the order of priority
defined in section 3.7. 
 Liquidation or dissolution 
 3.1.3. In the event of the dissolution or the liquidation of the Corporation or any other distribution of its property, shall have the right to share in the remaining property of the Corporation, subject
to the prior rights of other classes of shares, as defined in section 3.7. 
 Participation 

3.1.4. Shall participate in the profits or surplus assets of the Corporation. 
 3.2. CLASS “B” SHARES 
 Holders of Class “B” shares: 

Vote 
 3.2.1. Shall have the right to vote at
any meeting of the shareholders of the Corporation. Each Class “B” share confers one (1) vote. 
 Dividends 

3.2.2. Shall have the right to receive, as and when such dividends are declared, an annual maximal non-cumulative dividend of six percent (6%) on the
amount paid for said shares; such dividend shall be payable at the time and in the manner which the Directors may determine and subject to the order of priority as defined in section 3.7. 

  
 * Confidential
treatment requested 

 Participation 
 3.2.3. Subject to the provisions of subsection 3.2.2, shall not participate in the profits or surplus assets of the Corporation. 
 Redemption 
 3.2.4. Subject to the provisions of the Canada Business Corporations Act and the order
of priority defined in section 3.7, the Corporation will have the right to redeem Class “B” shares upon a thirty (30)-day written notice, at a price equivalent to the amount paid on said shares and any and all declared but yet unpaid
dividends on same. In the event of a partial redemption, such redemption shall be made in proportion with the number of outstanding Class “B” shares, without taking into account share fractions. A partial redemption may be made in any
other manner as unanimously approved by the shareholders of Class “B” shares. 
 Right to purchase 

3.2.5. Subject to the provisions of the Canada Business Corporations Act, the Corporation may, when it so deems advisable, without notice and without
taking into account any other classes of shares, purchase by mutual agreement, at the best possible price, all or part of the outstanding Class “B” shares, which price shall not exceed, in any way, the aforementioned redemption price.

 Liquidation or dissolution 
 3.2.6.
In the event of the dissolution or the liquidation of the Corporation or any other distribution of its property, shall have the right to be reimbursed for the amount paid on the Class “B” shares as well as the amount of any and all
declared but yet unpaid dividends on same, subject to the order of priority defined in section 3.7. 
 3.3. CLASS “C” SHARES

 Holders of Class “C” shares: 
 Vote 
 3.3.1. Subject to the provisions of the Canada Business Corporations Act, shall neither be
entitled to vote at any meeting of the shareholders of the Corporation, nor to receive a notice of such meeting nor to attend any such meeting. 

Dividends 
 3.3.2. Shall have the right to
receive, as and when such dividends are declared, an annual variable non-cumulative dividend of one percent to twenty percent (1% to 20%) on the amount paid for the said shares, payable at the time and in the manner which the Directors may determine
and subject to the order of priority as defined in section 3.7. 
 Participation 
 3.3.3. Subject to the provisions of subsection 3.3.2, shall not have the right to participate in the profits or surplus assets of the Corporation. 

  
 * Confidential
treatment requested 

 Redemption 
 3.3.4. Subject to the provisions of the Canada Business Corporations Act and the order of priority defined in section 3.7 hereof, have the right to demand from the Corporation, upon a thirty (30)-day
written notice, that the latter redeem the Class “C” shares that are held by the shareholder(s) at a price equivalent to the amount paid on said shares and any and all declared but yet unpaid dividends on same. In the event of a partial
redemption, such redemption shall be made in proportion with the number of outstanding Class “C” shares, without taking into account share fractions. A partial redemption may be made in any other manner as unanimously approved by the
shareholders of Class “C” shares. 
 Purchase 
 3.3.5. Subject to the provisions of the Canada Business Corporations Act, the Corporation may, when it so deems advisable, without notice and without taking into account any other classes of shares,
purchase by mutual agreement, at the best possible price, all or part of the outstanding Class “C” shares, which price shall not exceed, in any way, the aforementioned redemption price. 

Liquidation or dissolution 
 3.3.6. In the event
of the dissolution or the liquidation of the Corporation or any other distribution of its property, shall have the right to be reimbursed for the amount paid on Class “C” shares as well as the amount of any and all declared but yet unpaid
dividends on said shares, subject to the order of priority defined in section 3.7. 
 3.4. CLASS “D” SHARES 

Holders of Class “D” shares: 
 Vote

 3.4.1. Subject to the provisions of the Canada Business Corporations Act, shall netheir be entitled to vote at any meeting of the shareholders
of the Corporation, nor to receive a notice of such meeting nor to attend any such meeting. 
 Dividends 

3.4.2. Shall have the right to receive, as and when such dividends are declared, a monthly variable non-cumulative dividend of half of one percent to two
percent (0.5% to 2%) on the amount paid for said shares, payable at a time and in the manner in which the Directors may determine and subject to the order of priority as defined in section 3.7. 

Participation 
 3.4.3. Subject to the provisions
of subsection 3.4.2, shall not participate in the profits or surplus assets of the Corporation. 

  
 * Confidential
treatment requested 

 Redemption 
 3.4.4. Subject to the provisions of the Canada Business Corporations Act and the order of priority defined in section 3.7 hereof, have the right to demand from the Corporation, upon a thirty (30)-day
written notice, that the latter redeem the Class “D” shares that are held by the shareholder(s) at a price equivalent to the amount paid on said shares and any and all declared but yet unpaid dividends on same. In the event of partial
redemption, such redemption shall be made in proportion with the number of outstanding Class “D” shares, without taking into account share fractions. A partial redemption may be made in any other manner as unanimously approved by the
shareholders of Class “D” shares. 
 Purchase 
 3.4.5. Subject to the provisions of the Canada Business Corporations Act, the Corporation may, when it so deems advisable, without notice and without taking into account any other classes of shares,
purchase by mutual agreement, at the best possible price, all or part of the outstanding Class “D” shares, which price shall not exceed, in any way, the aforementioned redemption price. 

Liquidation or dissolution 
 3.4.6. In the event
of the dissolution or the liquidation of the Corporation or any other distribution of its property, shall have the right to be reimbursed for the amount paid on Class “D” shares as well as the amount of any and all declared yet unpaid
dividends on said shares, subject to the order of priority defined in section 3.7. 
 3.5. CLASS “E” SHARES Holders of Class
“E” shares: 
 Vote 
 3.5.1.
Subject to the provisions of the Canada Business Corporations Act, shall neither be entitled to vote at any meeting of the shareholders of the Corporation, not to receive a notice of such meeting nor to attend any such meeting. 

Dividends 
 3.5.2. Shall have the right to
receive, as and when such dividends are declared, a monthly variable non-cumulative dividend of half of one percent to two percent (0.5% to 2%) on the amount paid for the said shares, plus a redemption premium as defined in subsection 3.5.4.1,
payable at the time and in the manner which the Directors may determine and subject to the order of priority as defined in section 3.7. 

Participation 
 3.5.3. Subject to the provisions
of subsection 3.5.2, shall not participate in the profits or surplus assets of the Corporation. 
 Redemption 

3.5.4. Subject to the provisions of the Canada Business Corporations Act and the order of priority defined in section 3.7, have the right to demand from
the Corporation, upon a thirty (30)-

  
 * Confidential
treatment requested 

 
day written notice, that the latter redeem the Class “E” shares that are held by the shareholder(s) at a price equivalent to the amount paid for said shares plus the redemption premium
as defined in subsection 3.5.4.1, and any and all declared but yet unpaid dividends on same. In the event of partial redemption, such redemption shall be made in proportion with the number of outstanding Class “E” shares, without taking
into account share fractions. 
 3.5.4.1. The Class “E” share redemption premium shall be equivalent to the difference between the
amount paid for said shares and the fair market value of the consideration received at the time of issuance of same. Subject to the provisions of subsection 3.5.4.2, the fair market value shall be determined by the Board of directors of the
Corporation in accordance with generally accepted accounting principles and its decision shall be final, binding and without appeal. 
 3.5.4.2.
Should the competent tax authorities evaluate the fair market value of the transferred property in a different manner, and, following a final negotiation or a judgement rendered by a court of competent jurisdiction on the matter, the fair market
value thus obtained is different from the value established in subsection 3.5.4.1, it is understood that, in the event the fair market value is increased, the said premium shall be increased to match the difference, and that, in the event the fair
market value is reduced, the premium shall be reduced to take into account such difference. 
 3.5.4.3. If, between the date of issuance of the
Class “E” shares and the date at which the premium is adjusted as mentioned in subsection 3.5.4.2, some Class “E” shares of the share capital of the Corporation have been redeemed, the shareholders at the time of redemption will
have to, at the date of adjustment, make a cash payment to the Corporation or the Corporation will have to, at such date, make a cash payment to said shareholders, as the case may be, equal to the difference between the amount paid at the time of
the redemption of the shares and the amount that should have been paid to the shareholders if the adjustment had been taken into consideration. 

3.5.4.4. Furthermore, if dividends have been paid by the Corporation on some Class “E” shares between the date of issuance of the Class
“E” shares and the date at which the premium is adjusted according to subsection 3.5.4.2, the Corporation will have to, at the date of adjustment, make a cash payment to the holders of Class “E” shares at the time the dividend
was paid, or said Class “E” shareholders will have to, at the same date, make a cash payment to the Corporation, in order to compensate the other party for the insufficiency of the paid dividends or the overpayment of said dividends, as
the case may be, stemming from the fact that the redemption premium has been modified. 
 Purchase 

3.5.5. Subject to the provisions of the Canada Business Corporations Act, the Corporation may, when it so deems advisable, without notice and without
taking into account any other classes of shares, purchase by mutual agreement, at the best possible price, all or part of the outstanding Class “E” shares, which price shall not exceed, in any way, the aforementioned redemption price.

 Liquidation or dissolution 
 3.5.6.
In the event of the dissolution or liquidation of the Corporation or any other distribution of its property, shall have the right to be reimbursed for the amount paid on Class “E” shares as well as the amount of any and all declared but
yet unpaid dividends on said shares, subject to the order of priority defined in section 3.7. 

  
 * Confidential
treatment requested 

 3.6. CLASS “F” SHARES 
 Holders of Class “F” shares: 
 Vote 

3.6.1. Subject to the provisions of the Canada Business Corporations Act, shall neither be entitled to vote at any meeting of the shareholders of the
Corporation, nor to receive a notice of such meeting nor to attend said meeting. 
 Dividends 

3.6.2. In the event of a Class “A” shareholder’s death, shall have the right to receive, out of the funds which can legally serve this
purpose, a dividend whose amount shall be determined as hereinafter set forth. The dividend shall be declared and paid within three (3) months of the receipt by the Corporation of any proceeds from a life insurance policy following the death of
a Class “A” shareholder, subject to the order of priority defined in section 3.7. 
 The amount of the dividend is equivalent to the
amount by which the capital dividend account will be increased (as defined in subsection 89(1) (b) (iv) of the Income Tax Act and the equivalent sections of the Quebec Tax Act) upon receipt, by the Corporation, of any proceeds from any
life insurance policy following the death of a Class “A” shareholder. For this purpose, the directors will have to create a reserve fund equivalent to the increase of the capital dividend account as mentioned above, which said reserve fund
shall be distributed exclusively to Class “F” shareholders. 
 Participation 
 3.6.3. Subject to the provisions of subsection 3.6.2, shall not participate in the profits or surplus assets of the Corporation. 
 Redemption 
 3.6.4. An hour before the time as considered by any tax law to be “immediately
before the death” of a Class “F” shareholder, the Corporation must redeem all Class “F” shares held by such shareholder in priority to any other outstanding shares of the Corporation, at a price equivalent to the amount paid
to the Corporation at the time of their issuance plus any and all declared but yet unpaid dividends. 
 Issuance 

3.6.5. No Class “F” share may be issued as long as the dividends that Class “F” shareholders have a right to receive according to
subsection 3.6.2 have not been declared by the Board of Directors. 
 Purchase 
 3.6.6. The Corporation shall not be able to purchase Class “F” shares by mutual agreement. 

  
 * Confidential
treatment requested 

 Liquidation or dissolution 
 3.6.7. In the event of the dissolution or the liquidation of the Corporation or any other distribution of its property, shall have the right to be reimbursed for the amount paid on Class “F”
shares as well as the amount of any and all declared but yet unpaid dividends on said shares, subject to the order of priority defined in section 3.7 and the reserve fund as calculated in subsection 

3.7. Order of priority 
 3.7.1. The order of
priority applicable to all classes of shares of the Corporation with respect to the redemption, liquidation, dissolution or distribution of property is as follows: 
 Firstly, the Class “F” shares; 
 Secondly, the Class “E” shares; 

Thirdly, the Class “D” shares; 

Fourthly, the Class “C” shares; 

Fifthly, the Class “B” shares; 

Sixthly, the Class “A” shares; 

Notwithstanding the above-mentioned order of priority, shareholders of a class of shares may renounce to the above-mentioned order of priority by
unanimous approval by all shareholders of said class of shares. 
 Schedule / Annexe 

Restrictions on Share Transfers / Restriction sur le transfert d’actions 

4. RESTRICTION ON SECURITIES TRANSFERS 
 4.1.
Subject to subsection 4.2, no securities of the Corporation, other than non-convertible debt securities, can be transferred without: 
 4.1.1.
The approval of the Directors of the Corporation. Such approval must be in written form duly signed by the majority of the Directors or by resolution of the Board of Directors; or 
 4.1.2. The approval of the Shareholders of the Corporation. Such approval must be in written form duly signed by the holder(s) of the majority of the outstanding shares of the share capital of the
Corporation or by resolution of the Shareholders. 
 4.2. There shall be no restrictions on the transfer of securities following the death of a
shareholder. 

  
 * Confidential
treatment requested 

 Schedule / Annexe 

Other Provisions / Autres dispositions 
 7. OTHER PROVISIONS 
 BORROWING POWERS 
 7.1. The Board of Directors may, by resolution and without the approval of the shareholders: 

7.1.1. Borrow money, taking into account the credit of the Corporation; 
 7.1.2. Issue, reissue, sell or pledge the Corporation’s debt instruments; 
 7.1.3. Guarantee
in the name of the Corporation the execution of an obligation of which another person is responsible. 
 7.1.4. Delegate one or many of the
aforementioned powers to a director, a committee of directors or to an officer of the Corporation. 

  
 * Confidential
treatment requested 

  
 

 

  
 * Confidential
treatment requested 

  
 

 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested 

 

 

  
 * Confidential
treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]